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ABSTRACT 
 
 
Avian metapneumovirus (AMPV) is an enveloped negative sense single 
stranded RNA virus which is a major endemic respiratory pathogen of global 
domestic poultry. Since reverse genetic (RG) techniques have been applied to 
this pathogen several reports have investigated the effects of single and 
multiple genomic mutations and gene deletions or insertions on viral biology. 
The aim of this study was to gain a better understanding of the viral capacity to 
accept and in some cases express homologous and heterologous extra 
sequences. 
Initially an AMPV subtype A was modified to introduce a homologous 
200 bp sequence within the G gene and this recombinant was suggested to be 
used as a positive control for validating all stages of a previously established 
RT-nested PCR.  
Different Green Fluorescent Protein (GFP) AMPV recombinants were 
then prepared each one containing the reporter gene in a different intergenic 
position and then were assessed for expression, stability and viability. In 
particular, quantification of the expression was calculated using a quantitative 
ELISA. All recombinants showed high stability, while good viability was 
observed in all the positions, except when GFP was inserted between 
nucleocapsid (N) and phosphoprotein (P). The highest expression was detected 
in the virus with the insertion between N and P as expected, according to the 
transcriptional model for non-segmented negative stranded viruses. However 
GFP was produced at high levels even when inserted at the trailer end 
intergenic positions. Poor expression was seen for all the other positions. 
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The vectoring abilities of subtype A strains were further investigated to 
accept and express foreign genes, specifically GFP gene and both spike (S1) and 
nucleocapsid (N) genes of infectious bronchitis virus (IBV). After viruses had 
been recovered by RG, all recombinants were proven to express the inserted 
genes efficiently and were all found to be highly stable during passage in vitro. 
Subsequently IBV recombinants were tested as candidate vaccines by eye-drop 
inoculation of one-day-old chickens. When chicks were challenged with IBV, 
partial protection results were observed, as assessed by greater motility of 
tracheal cilia from animals receiving the recombinants.  
Finally the development of a new RG system was attempted in order to 
extend this type of studies to the B subtype. This subtype is distributed 
worldwide and growing field evidence suggests it to be more able to infect 
commercial chickens compared to subtype A. For this reason it would be 
convenient to have an RG available also for B viruses. The construction of a 
DNA copy of the viral genome was attempted using site-directed mutagenesis 
and ligation techniques, resulting in more than 85% of the genome cloned. 
Unfortunately full genome cloning proved to be not possible, as severe 
problems were encountered, including construct instability and cloning 
bacteria intolerance to viral sequences.  
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  INTRODUCTION 
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In the late 1970 in South Africa a severe pathological condition of 
turkeys, characterized by an acute rhinotracheitis, hit the local poultry industry 
heavily (24). Although many previously known respiratory pathogens could 
have been responsible for such a condition, no immediate diagnosis was made. 
Subsequent analysis pointed to an unknown viral agent, promptly named 
Turkey rhinotracheitis virus (TRTv), as cause of that epizootic (24). The virus was 
later charachterized as a negative sense, non-segmented, single stranded RNA 
virus closely related to mammalian respiratory syncytial viruses (178). For this 
reason it was classified within the Paramyxoviridae family, subfamily 
Pneumovirinae, genus Pneumovirus (178). More recently, following the 
detection of a similar virus infecting humans, TRTv was then placed in a new 
genus, Avian metapneumovirus (AMPV) (224). After its first detection in Africa 
(24) AMPV spread rapidly to Europe (7) and then to most parts of the world 
(50), becoming immediately a major problem for turkey production, but also 
for chickens, which soon proved to be susceptible to it. Losses were mainly due 
to a decreased bird growth rate and sometimes to high mortalities caused by 
secondary bacterial infections (205). Furthermore field and experimental 
evidence showed the viral capacity to affect egg production in laying birds, 
both in terms of number of laid eggs and egg quality (69, 190). Up to now 
AMPV control has been possible only by using live attenuated and killed 
vaccines (89). However, this approach has been shown to be limited, especially 
regarding eradication; also live vaccines have sometimes been shown to revert 
to virulence in turkeys (30) and as different viral subtypes are present, 
protection is often limited to certain strains (51). On the other hand killed 
vaccines appeared to be ineffective in preventing the respiratory infection, and 
are mainly administered to protect against egg drops (51). 
Due to the unsatisfying results obtained using the above mentioned 
strategies, researchers have started to apply new generation techniques, not 
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just to develop better vaccines but even to reach a better understanding of 
viral biology (91, 123, 158, 179). In 2004 the first AMPV reverse genetic system 
(RG) was developed (158), enabling the recovery of the RNA virus from a DNA 
copy (cDNA) of its genome. As DNA molecules are more stable and easily 
modifiable than RNA ones, RG has given the opportunity to scientists to 
introduce not only single or multiple mutations, but also deletions and 
insertions into the AMPV genome and, followed by viral rescue, to readily 
observe the effects of those modifications on virus biology. 
In 2004 an RG system was specifically developed for subtype A of AMPV 
(158). This thesis has investigated the ability of this subtype to accept, tolerate 
and express inserted foreign sequences. Moreover an attempt to adapt this 
technique to subtype B was made. 
In Chapter 2, a homologous M2 gene sequence of approximately 200 bp 
was introduced into the G gene using restriction endonuclease cut properties 
and ligation steps. The insertion was made in a such way as to increase the size 
of a common AMPV diagnostic RT-PCR amplicon of the G gene. Rescued virus 
proved to be unaffected, at least in vitro, by the insertion, and it was proposed 
as positive control for diagnostic PCRs. 
Chapter 3 investigates the positional effects of inserts on AMPV. 
Current transcriptional models for non-segmented negative stranded RNA 
viruses suggest 3’ upstream genes to be transcribed more efficiently than 
downstream ones. As polymerase entries the genome only in that position, 
messenger RNAs are produced in a polar and sequential way, which gradually 
decrease due to polymerase dissociation. This results in a major transcription 
and then protein synthesis of genes close to the 3’ end compared to the 5’ end 
ones. Seven different recombinants carrying GFP were constructed, each one 
expressing the insert in a different intergenic position. Recombinant viruses 
were passaged, sequenced and finally titrated according to two different 
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methods. GFP expression was verified both by fluorescence observation and by 
specific ELISA. The latter enabled not only the detection of GFP but also 
quantification of the amount of protein produced. 
Chapter 4 describes the modification of the AMPV genome to be able to 
accept and express foreign genes. Extra gene transcriptional starts and stops 
were included into different intergenic regions so that genes could be inserted. 
To assess the system, green fluorescent protein was initially added in different 
positions. Once expression was verified, observing the fluorescence under UV 
microscope, AMPV recombinants carrying infectious bronchitis virus (IBV) S1 
and nucleocapside genes were constructed. After in vitro studies assessing 
foreign gene expression, stability, viability and cytopathogenicity, recombinant 
viruses were used as vaccine candidates against IBV in chicken experimental 
infections.  
Finally, Chapter 5 describes the attempt to construct a subtype B 
reverse genetics system. While for A and C subtypes such a technique has been 
successfully applied, for subtype B, despite several efforts having been made, 
RG has not yet been successful. As a first step a cDNA of a full length B subtype 
genome had to be constructed by cloning viral PCR amplicons in a plasmid, 
followed by the construction of plasmids encoding for essential AMPV support 
proteins. This procedure has proved to be very critical in view of plasmids 
instability and intolerance of the cloning bacteria to certain viral sequences. 
The thesis is opened by an initial chapter (Chapter 1) reviewing all the 
general aspects regarding Avian metapneumovirus, as described by the 
innumerable studies which have been carried out since AMPV presence was 
revealed about 30 years ago. As science is formally communicated through 
scientific articles, which have usually a fixed and formal structural organization, 
including introduction, material and methods, results and discussion 
paragraphs, we have decided to write every chapter as an independent paper, 
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each one with its own sections. A further chapter, stating final discussions, 
closes the thesis. 
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  CHAPTER 1 
AVIAN METAPNEUMOVIRUS LITERATURE REVIEW 
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1.1 AETIOLOGY 
 
1.1.1 Taxonomy 
 
Avian metapneumovirus (AMPV) is one of the two viral species, with 
human metapneumovirus (HMPV), belonging to the Metapneumovirus genus; 
Metapneumoviruses are part of the subfamily Pneumovirinae within the 
Paramyxoviridae family, including single stranded, negative sense RNA, and 
enveloped viruses (178, 224, 226). 
 
1.1.2 Morphology  
 
Viral particles are characterized by high pleomorphism (Figure 1), both 
in size and length; virions can be spherical or have a filamentous form, usually 
of 40 – 500 nm, but sometimes even over 1000 nm. Their nucleocapsids have a 
helical shape and on the envelope surface projections of about 13 – 14 nm are 
clearly distinguishable (11, 25, 46, 51, 84, 86, 145, 240). 
 
Figure 1: AMPV observed under electronic microscope 
(provided by Prof. R.C .Jones) 
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1.1.3 Genome 
 
The viral genome consists of a single negative stranded RNA of about 
13000 - 14000 nucleotides (181). It encodes for 8 genes (Figure 2) which lead to 
the synthesis of at least 9 proteins: starting from the 3’ end, we can recognize 
in order N, P, M, F, M2 (including two overlapping open reading frames), SH, G 
and L (70, 132). Every gene is flanked by a transcriptional start sequence and a 
transcriptional stop, and between each transcriptional units there are 
intergenic untranslated regions.  At the leader (3’) and trailer (5’) ends, other 
untranslated sequences of about 40 nucleotides are known, containing 
promoters and regulatory sequences for transcription, replication and 
packaging (91, 132, 233). 
 
 
Figure 2: AMPV genome 
 
1.1.4 Proteins 
 
Each gene encodes for the homonym protein. The Nucleocapsid protein 
(N) forms the integral part of the nucleocapsid: tightly joined to the genome, it 
provides the typical helical structure. N is an essential part, with the 
Phosphoprotein (P) and the Polymerase (L), of the ribonuclear complex. L and P 
are therefore critical for replication and transcription, and they function 
respectively as a catalytic and non-catalytic factor in these processes. The 
Matrix protein (M) is situated in the inner envelope surface, anchoring the 
nucleocapsid to the lipidic membrane. AMPV has got an accessory Matrix gene 
(M2), encoding for two different proteins: M2-1, which seems to behave as a 
transcription elongation factor and M2-2, which has shown transcription 
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inhibition properties. The small hydrophobic protein (SH) is an integral 
membrane polypeptide; however its function is poorly understood. The Fusion 
(F) and the Attachment (G) proteins are located on the external part of the 
envelope and are the major antigenic determinants (21, 48, 70). 
 
1.1.5 Virus Attachment and Entry 
 
Viral particles interact with the host cells using the surface proteins 
(131). The G protein enables virus attachment on the cell receptors, while F 
promotes the fusion of the envelope with the cell membrane; the nucleocapsid 
is then released in the cytoplasm, where AMPV replication occurs (70, 77). 
 
1.1.6 Replication and Transcription models 
 
AMPV follows the generally accepted replication and transcription 
models for other Mononegavirales.  While plus-stranded RNA viruses possess a 
genome able to function immediately as a messanger RNA, and for this reason 
able to synthetize immediately all viral proteins, negative single stranded RNA 
viruses require the ribonuclear complex both for transcription and replication. 
This means their genome needs to be encapsidated with the nucleoprotein (N) 
and associated with the RNA dependent polymerase (L) and its cofactor (P) to 
initiate the infectious cycle. The polymerase can enter the genome only at the 
3’ leader end, and as it moves along the RNA, it encounters a transcriptional 
start signal; a messenger RNA (mRNA) starts then to be synthetized and the 
process stops when a transcriptional stop signal is met. The polymerase 
molecules at this stage have got two possibilities: half of them will dissociate 
from the genome and will rebind again from the 3’end, and the other half will 
move along and at the next transcriptional start will begin to transcribe a new 
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gene. This mechanism regulates all the transcription process until the end of 
the viral genome, meaning a good number of polymerase molecules will 
dissociate at every gene junction. This results in a sequential and gradually 
decreasing mRNA production: the genes located proximally will be transcribed 
in higher quantity compared to the ones placed distally. A minor or major 
amount of mRNA will result in a minor or major protein production (68, 229, 
233). 
Replication starts with the synthesis of a complementary positive copy 
of the genome, called antigenome. This is used as a template for genome 
production. During replication the polymerase ignores the transcription start 
and end signals, reading fully through all the viral RNA. The mechanisms that 
permit the polymerase to behave differently during transcription and 
replication are not clear, but some studies on human respiratory syncytial virus 
indicate that the concentration of N may be critical in regulating this process 
(76, 91, 233). 
 
1.1.7 Packaging and Assembly 
 
Nucleocapsid formation starts with the association of viral RNA with the 
N protein, immediately followed by P and L (126). This leads to the formation of 
the ribonuclear complex, that is the functional unit of the virus both for 
replication and transcription (229). The M protein concentration seems critical 
in final assembly, as this protein is able to interact firstly with the ribonuclear 
complex (including N, P, L and the viral genome), located in the cytoplasm, and 
then with the surface proteins (G, F and SH), which after synthesis, have been 
inserted into the cell membrane; these last interactions, in particular, results in 
virions budding from the cell surface (70, 171, 210).  
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1.1.8 Strain Classification 
 
Four subtypes of AMPV have been identified: A, B, C and D. Early 
studies, which showed differences among AMPV strains using monoclonal 
antibodies (45, 57) and sequencing and amino acidic analysis (122, 157), 
suggested the existence of two subtypes, A and B. In 1997, following the first 
North American AMPV outbreak (193), subtype C was identified. Both 
serological (55) and genomic techniques (194, 195) have highlighted the 
differences with the previous subtypes. Finally retrospective analysis of French 
strains, isolated in 1985, resulted in the identification of subtype D (12, 213). 
 
1.1.9 Physical and Chemical Susceptibility 
 
AMPV is stable at pH range from 3.0 to 9.0, sensitive to lipid solvents 
and inactivated at 56˚C for 30 minutes (46, 89). Subtype C is reported to be 
resistant to cold temperatures (at -70 and - 20 ˚C for more than 26 weeks), but 
a viral survival is dramatically decreased at higher temperatures (only 6 hours 
at 50˚C). Many disinfectants, e.g. ethanol, ammonia, iodophor, phenol 
derivates and hypochlorite, are effective against AMPV. Moreover the virus 
was resistant to drying for 7 days (217) but could survive for several days in 
turkey litter at different temperatures (227). Finally more recent studies have 
proposed microwaving, autoclave treatment (71) and high pressure processing 
as convenient and easy methods for viral inactivation (134). 
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1.2 EPIDEMIOLOGY 
 
 
1.2.1 Distribution 
 
AMPV has been detected worldwide, with the only exception of 
Oceania (14). The disease appeared for the first time in South Africa in the late 
’70 (25), and then spread to Europe (6, 7, 18, 19, 73, 75, 99, 150, 177), Asia (82, 
135, 168, 221, 231), South and Central America (8, 66, 115, 216) and other 
African countries (26, 105, 169).  In North America it has been reported only 
since 1996 (198). 
Subtypes A and B are responsible of the disease in all affected 
continents, with the only exception of North America, where infections are 
caused just by AMPV subtype C. Subtypes C related strains have been more 
recently detected in France (212) and Korea  (130). Subtype D was isolated only 
once in France in 1985 (12). 
 
1.2.2 Hosts 
 
Turkeys and chickens of all ages are the natural hosts (89). In particular 
the first species seems to be the most susceptible. Guinea fowls and pheasants 
are also sensitive to AMPV infections (33, 87, 88, 175), while Pigeons, geese 
and ducks were believed to be resistant (87); however recent studies have 
suggested a sensitivity of waterfowls to subtype C (203, 215). Antibodies 
against AMPV have been detected also in farmed Ostrich in Africa (26). Wild 
birds sensitivity to AMPV has been proved only for subtype C (15, 16, 203, 220), 
while for subtype A and B this issue remains poorly understood (67, 101). Avian 
Metapneumovirus is not considered a zoonotic pathogen but recent serological 
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surveys suggest that occupational exposure to turkeys might be a risk factor for 
human infection (124). 
 
1.2.3 Transmission 
 
Direct contact transmission seems to be the only demonstrated way of 
infection, both directly with infected animals or their respiratory discharges (2, 
5, 61, 145). Other transmission ways have been supposed (201), e.g. vertical 
(121, 125) or through contaminated water, equipment, feed truck or 
personnel, but no real evidence was demonstrated until now (115). In the USA 
migratory species have been recognized as a possible viral source, although 
transmission between wild and domestic birds remains to be proved (89). 
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1.3 PATHOGENESIS 
 
 
The upper respiratory tract is considered to be not just the first 
replicative site of the virus but also the main target tissue for viral replication. 
AMPV seems to have a particular tropism for the ciliated cells of the nasal 
cavities, conchas, infraorbital sinus and trachea. In these organs viral particles 
can be detected until 7-9 days post infection using immunofluorescence 
technique (121) and isolated until 14 days post infection (53) in turkeys. Similar 
findings have been demonstrated also in chickens (32). However, occasionally 
AMPV can reach the lungs and the air sacs (5, 32, 58, 139). Bacterial co-
infections seem to facilitate viral penetration along the lower respiratory tract: 
Escherichia coli (1, 219, 223), Bordetella avium (61, 113), Mycoplasma 
gallisepticum (156) and imitans (80), Riemerella anatipestifer (187), 
Chlamydophila psittaci (225), Ornithobacterium rhinotracheale (142) have all 
proved to exacerbate the disease and to enhance virus distribution in infected 
birds. On the other hand, concurrent infections with infectious bronchitis virus 
appeared to inhibit replication of AMPV (118). It is still not clearly understood 
how the virus can infect other organs outside the respiratory system, but it is 
common to detect AMPV mainly in the reproductive tract (49, 104, 121, 206, 
228) and on some occasions in the Harderian gland, kidneys (125), spleen, cecal 
tonsil and bursa of Fabricious (9). A short transient viraemia could explain this 
behavior, although AMPV has been rarely found in the circulation (202). Some 
authors have suggested, supported by in vitro studies with subtype C, that 
macrophage cells are particularly susceptible to AMPV and to possibly be 
responsible of viral dissemination (200). No clear differences have been found 
in the pathogenesis among different subtypes: different results seems more 
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related to the virulence of the single strain than to the subtype belonging (9, 
202, 222). 
 
 
1.4 DISEASE IN BIRDS 
 
 
The clinical picture of AMPV infection is typically characterized by 
respiratory symptoms: coughing, sneezing, nasal discharge, swollen infraorbital 
sinus, but even conjunctivitis and submandibular oedema can be present (25, 
117, 145). The disease is also called turkey rhinotracheitis (TRT) as this species 
appears to be more severely affected compared to chickens, where often the 
infection is asymptomatic (50). Morbidity is usually very high (almost 100%), 
while mortality can be very variable (172). The severity of the disease is highly 
dependent on management factors, including bird density, ventilation, 
temperature, hygienic conditions, and on secondary bacterial infections (89, 
96, 205). Co-infections of AMPV and E.coli have been associated in chickens 
with swollen head syndrome (SHS). This is characterized not just by respiratory 
signs but also of a general head swelling (Figure 3), which leads to neurological 
signs, such as disorientation, torticollis and opistothonus (96, 120).  
AMPV infections cause drop in egg production in laying birds.  Drops in 
egg production are usually of the order of 10-20% (190), which can reach even 
70% (239) in turkeys. Egg quality is affected, showing poor and thin shells (69). 
Drops in egg production have been reported in field in laying hens too, 
although in experimental conditions have never been seen after experimental 
respiratory challenge. In contrast to the situation in turkeys, only intravenous 
injection of virus is able to decrease the laying performance in chickens (52, 
104, 206).  This difference between the two species has never been explained.  
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Figure 3: SHS in chicken (provided by Prof. E. Catelli) 
 
 
1.5 POST-MORTEM FINDINGS 
 
 
1.5.1 Gross Lesions 
 
While in turkeys gross lesions, due to uncomplicated infections, are a 
considerable finding, in chickens these are quite uncommon (89). In turkeys, 
lesions include the presence of watery to mucoid exudate in the upper 
respiratory tract, swelling of the infraorbital sinus caused by accumulation of 
mucus, conjunctivitis and submandibular oedema (205). In breeders, prolapsed 
oviducts, folded shell membrane in the reproductive tract and egg peritonitis 
may be seen (121). Bacterial secondary infection can aggravate these findings, 
resulting in airsacculatis, pericarditis and perihepatitis (205). In chickens, during 
SHS presence, head and neck may increase in size and be swollen, due to an 
accumulation of a yellow gelatinous or even purulent oedema in the 
subcutaneous tissue (176). 
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1.5.2 Microscopic Lesions 
 
No major differences have been found between turkeys and chickens. 
As said previously AMPV has a particular tropism for epithelial cells. The main 
histological lesions are located on the respiratory epithelium, characterized by 
deciliation, deepithelization, thickening of the mucosa, hyperaemia, 
mononuclear infiltration and glandular proliferation in the turbinates, 
infraorbital sinuses and trachea (Figure 4). Lesions are usually transient and 
detectable in the first 10 days after infection. After 3 weeks, birds are totally 
recovered (9, 32, 114, 222). Epithelial damages in the oviduct have been also 
observed (52). 
 
 
Figure 4: microscopic lesions in trachea after AMPV infection 
(provided by Prof. E. Catelli) 
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1.6 IMMUNITY 
 
 
The immune reactions of turkeys towards AMPV infections have not 
been fully clarified. Some studies speculated cellular mediated immunity to be 
critical for protection, while humoral immunity appears to be not critical, and 
circulating antibody titers do not seem to be an indicator of protection (182). In 
experimental infections, turkeys with no detectable antibodies were protected 
against challenge with a virulent strain (62) and vaccinated bursectomised 
poults were resistant to challenge (119). Furthermore suppression of T- 
lymphocytes with cyclosporine A caused delayed recovery from clinical signs 
and more lasting microscopic lesions (186). Local immunity could be related in 
resistance to infection, however, as suggested for other respiratory pathogens 
(79), its short duration might explain recurrent infections during birds 
productive life in farms (182). Maternal antibodies are passed from hens to 
their progeny via the egg yolk, but their role does not seem to be significant, as 
they do not prevent infections (162) or do not interfere with early vaccination, 
allowing young chicks to be immunized in early stages (62) or directly in ovo 
(237). 
 
 
1.7 DIAGNOSIS 
 
 
Both clinical and post-mortem findings are not specific for AMPV as 
they can be similar to those caused by other viral respiratory pathogens such as 
Newcastle disease, infectious bronchitis, low pathogenic avian influenza, 
mycoplasmas or respiratory bacterial infections. Viral identification is therefore 
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critical for a definitive diagnosis. This target can be reached directly by isolating 
or detecting the virus, or indirectly, by demonstrating specific serological 
responses in the host (90). 
 
1.7.1 Direct Diagnosis 
 
AMPV has a very short persistence in the host before clearance, both in 
turkeys (53) and chickens (32). For this reason virus isolation and detection are 
not always easy. Samples must be taken in the very early stages (at 3-5 days 
after infection) from birds not yet showing clinical signs (51). 
 
1.7.1.1 Isolation 
 
Primary isolation of AMPV is possible using tracheal organ culture (TOC)  
(145) or embryonated eggs inoculated via the yolk sac (25, 170). Both methods 
seem to have good sensitivity (51), but isolation of subtype C in TOC is not 
suitable as this strain does not cause ciliostasis (55). Once isolated, AMPV can 
be easily adapted to grow in different cell lines such as Vero (25) or in chick 
embryo fibroblasts (94) and chick embryo liver cell monolayers (235). The 
cytopathic effect (CPE) is not specific and often characterized by the presence 
of small cyncytia (25, 112). Other cell lines have been suggested both for 
primary isolation and viral passages, such as QT-35 (93), primary turkey 
turbinate (127), turkey and chicken kidney cells (127), BGM, DF-1 (211), CER 
and BHK-21 (64), but are not commonly in use. 
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1.7.1.2 Viral Detection 
 
Different immunochemical methods have been used to detect viral 
antigens in fixed and unfixed tissues and smears (89). Immunoperoxidase (32, 
111, 139), immunofluorescence (116, 121) and immunogold staining (165)  
have been widely used during scientific studies. Specific monoclonal antibodies 
and immunodiffusion tests have been also used to differentiate between viral 
subtypes (45, 57, 90). All these methods appear to be time consuming and not 
particularly sensitive and they have been almost totally replaced by molecular 
methods, especially for diagnostic applications (89).  
RT-PCRs amplify portions of viral genome, allowing a more rapid 
detection. Furthermore its high sensitivity enables viral presence to be 
revealed for a longer period compared to isolation methods or other detection 
techniques (51). Several PCR protocols have been described. A PCR based on 
the highly conserved N gene has proved to be able to detect all four AMPV 
subtypes (13). Subtype specific PCRs have been suggested targeting more 
variable genes like G (13, 154) and F (109, 143) for subtypes A and B and M for 
subtype C (4, 173). Real Time PCR protocols have been also developed, allowing 
not just a more sensitive viral detection but even viral quantification (41, 95). 
Multiplex RT-PCR have also been tested, able to detect AMPV and other 
respiratory viruses such as Influenza, Newcastle Disease and IBV (3, 83, 140). 
 
1.7.2 Indirect Diagnosis 
 
As antibodies against AMPV have been proved to be detectable for at 
least 89 days in sera after infection (121), serological tests are commonly used 
to confirm infection, especially in commercial poultry (89). Virus neutralization 
(VN), indirect immunofluorescence (IIF) (Figure 5), and enzyme-linked 
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immunosorbent assay (ELISA) tests have all been used. However while the first 
two are mainly employed for research work, ELISA is now the most common 
serological AMPV test, due to its sensitivity, specificity and suitability for mass 
serological screening. Several commercial kits have been developed (49, 89).  
Performances are highly dependent on the coated antigen: homologus tests 
have shown a higher efficiency compared to heterologous ones, especially 
among different subtypes (51, 148, 214). This can give rise to false negatives 
and the illusion that a vaccine has not ‘taken’. Subtype C antibodies are 
detected very poorly by subtype A and B ELISA, leading to the production of 
subtype C specific test (55, 138). Finally Blocking ELISAs are available in order to 
detect antibodies originated from sera of any avian species (33, 218). 
 
 
Figure 5: IIF positivity to AMPV on tracheal section 
(provided by E. Catelli) 
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1.8 CONTROL 
 
 
As specific therapy against AMPV is not available, a preventive 
approach is critical both in avoiding the infection of birds and in controlling 
eventual losses caused by the disease. Attention to hygiene and biosecurity 
practices, ventilation, temperature, density, stress control, disinfection and 
good management procedures are all critical in reducing symptomatology and 
mortality (89, 205). Antibiotics can be used to prevent secondary bacterial 
infection (42, 97). 
 
1.8.1 Vaccination 
 
AMPV infections can be prevented by vaccination. Several vaccines are 
available and commonly used in commercial birds. Live attenuated vaccines are 
usually administrated by several methods (intranasal, eye-drop, drinking water 
or spray) to all bird categories at early stages to prevent the respiratory 
symptomatology (49, 89). While in broilers one administration seems to be 
fully protective, in growing turkeys repeated vaccination are required. Laying 
birds are usually vaccinated prior to the onset of lay by injection of inactivated 
vaccines, to avoid egg production losses (49, 63). Good cross protection has 
been reported between A and B subtypes (56, 74, 214). On the other hand, 
subtype C vaccines do not protect against A and B subgroups (55). 
Simultaneous vaccination with AMPV and other respiratory viruses (IBV, NDV) 
is not advised by pharmaceutical companies. However, experimental studies 
have shown no interference in protection onset (54, 79, 81). In ovo 
administration of live AMPV vaccines has been also tested by different research 
groups with good results (103, 208, 237). Recombinant and subunit vaccines 
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have been recently developed and evaluated, however with poor outcomes at 
the time of writing, compared to conventional vaccines (107, 123, 179, 209). 
 
 
1.9 REVERSE GENETICS 
 
 
In 2004 Naylor et al. developed the first reverse genetic system for 
AMPV (158).  A full length (FL) cDNA of subtype A was cloned in a plasmid 
vector by a series of PCR and ligation steps. The plasmid included a kanamicyn-
resistant gene, essential in the cloning process, a T7 promoter and Hepatitis 
delta virus ribozyme. (158). N, P, L and Matrix 2 (M2) single genes, lead by a T7 
promoter, were also cloned in other plasmids in order to provide the genome 
with the essential protein to form the RNP complex.  Viral rescue was 
performed on Vero cells, previously infected with a recombinant Fowlpox virus 
expressing the bacteriophage T7 polymerase. This polymerase is able to 
recognize the T7 promoter inserted in the plasmids and then to initiate 
transcription directly from them. Therefore the addition of the full length cDNA 
and the four support protein genes, in the presence of lipofectamine 2000 to 
allow cDNAs entrance into cells, should lead to the formation of all the RNP 
components (158). After the complex has been established, genome replication 
and gene transcription can begin as occur naturally, producing new RNA 
virions. A similar system, based on the same technical principles, was 
constructed for subtype C in 2006 in the United States (92). Up to now it has 
not yet been possible to apply RG system for subtype B.  
Since RG has been applied to AMPV (92, 158) several works have 
investigated the effect of single and multiple genomic mutations (23, 160, 163) 
but also of gene deletions (133, 243) and insertions (92, 136) on viral biology. 
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AVIAN METAPNEUMOVIRUS RT-NESTED PCR: A NOVEL 
FALSE POSITIVE REDUCING INACTIVATED CONTROL 
VIRUS WITH POTENTIAL APPLICATIONS TO OTHER RNA 
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2.1 ABSTRACT 
 
 
Using reverse genetics, an Avian metapneumovirus (AMPV) was 
modified for use as a positive control for validating all stages of a popular 
established RT-nested PCR, used in the detection of the two major AMPV 
subtypes (A and B). Resultant amplicons were of increased size and clearly 
distinguishable from those arising from unmodified virus, thus allowing false 
positive bands, due to control virus contamination of test samples, to be 
readily identified. Absorption of the control virus onto filter paper and 
subsequent microwave irradiation removed all infectivity while its function as 
an efficient RT-nested- PCR template was unaffected. Identical amplicons were 
produced after storage for one year. The modified virus is likely to have 
application as an internal standard as well as in real times methods. Additions 
to AMPV of RNA from other RNA viruses, including hazardous examples such 
HIV and Influenza, are likely to yield similar safe RT-PCR controls.  
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2.2 INTRODUCTION 
 
 
Avian metapneumovirus (AMPV) causes major disease in poultry in 
most of the world and its detection and characterization has assisted (84, 98, 
145, 234), and continues to assist (34, 39), in vaccine selection and disease 
control. RT-PCR is a powerful technique for detecting many viruses through the 
presence viral RNA in diagnostic samples. For Avian metapneumovirus (AMPV) 
tests have been reported (38, 110, 154, 167) which offer a sensitivity generally 
similar to, or greater than, classical virus isolation while additionally extending 
detection beyond loss of replicative viability (154), as well as frequently 
informing of virus origins through RNA sequence analysis (31, 34). Furthermore 
this sequence analysis avoids the need for secondary virus identification as 
often required in isolation techniques (17). 
For PCR tests a positive control DNA sample generally accompanies 
sample tests to ensure the detection system is functional. However its cross 
contamination of test samples can lead to false positive readings (128).  For RT-
PCR tests, a control RNA is equally necessary and generally takes the form of an 
established control virus, but again its cross contamination of samples can be 
confused with true positive detections. This paper describes the construction 
and testing of a novel positive control AMPV able to identify such cross 
contamination events by producing amplicons of increased sizes, readily 
distinguishable from field virus amplicons on agarose gels, when used in 
conjunction with an established G gene based RT-nested-PCR method, (154).  
The established RT-nested-PCR method, distinguishing between AMPV 
subtypes A and B, has been in common use since 1995 and is outlined in Figure 
6. Briefly, genomic sense primer G6- primes from antigenome sense RNA to 
yield a DNA copy. This is amplified using the same primer together with 
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antigenomic sense primer G1+. The resultant amplicon is further amplified 
using subtype specific PCRs whereby common primer G5- is paired with G8+A 
for subtype A specificity and G9+B for subtype B specificity.  Subtype A and B 
viruses result in bands of 268 bp and 361 bp respectively and are readily 
distinguished on agarose gels.    
More recently, the presence of the AMPV G gene was demonstrated 
unnecessary for AMPV virus growth in Vero cells (133, 158, 160) and this made 
possible the generation of viruses with dysfunctional or absent G genes by 
reverse genetics (158, 161).  This also led to the possibility of generating viable 
diagnostic RT-PCR control viruses containing major G gene modifications. The 
current study describes the construction and testing of a novel subtype A Vero-
grown RT-nested-PCR positive control virus possessing two G gene 
modifications, with one conferring subtype B primer specificity and the other 
resulting in RT-nested PCR amplicons of increased size. Subsequently, the virus 
was absorbed onto filter paper and inactivated by microwave radiation to yield 
a stable, non-infectious standardized control sample.  
 
 
Figure 6: Schematic diagram showing the usage of oligonucleotide primers in the established RT-
nested-PCR for detecting RNA from either subtype A or B AMPVs. 
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2.3 MATERIALS AND METHODS 
 
 
Establishment of an AMPV control virus. A full length (FL) cloned viral 
copy of a subtype A AMPV LAH A (158) was modified in two stages; initially to 
add B type specificity, then a spacer was added to yield amplicons of increased 
size. Modifications are outlined in Figure 7 and details are given below.  
AMPV full length copy: addition of G9+B sequence.  A full-length DNA 
copy of AMPV LAH A was modified by site directed mutagenesis to introduce 
the subtype B G gene primer sequence, G9+B (Table 1) at the equivalent 
position in the subtype A G gene, as shown in Figure 7 (a).  Briefly primer Ga-
G9+b contained the sequence of G9+B flanked by subtype A sequence and Ga-
G9-b contained the exact reverse compliment sequence. Annealing of these 
primers to the cloned LAH A copy and extension using pfu turbo, led to a nicked 
modified full length copy which was used to transform Invitrogen STB12 cells as 
previously described (22, 43, 161). Colonies were screened for the presence of 
the correct sequence by PCR using G9+B and G5- primers.   
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Figure 7: Outline of the stages involved in modification of the LAH A full length copy 
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Table 1: Oligonucleotide primers used in the RT-nested-PCR or construction of the modified full length cDNA 
PRIMER SEQUENCES 
G 1 + gggacaagtatctctatg 
G 6 - ctgacaaattggtcctgatt 
G 8 + A cactcactgttagcgtcata 
G 9 + B tagtcctcaagcaagtcctc 
G 5 - caaagagccaataagccca 
M2.2 Xho + gtgcaatgctcgaggattgtgtatgg 
M2-SH Xho - ccatacacaatcctcgagcattgcac 
Sal Ga 235 - ggctgctcctgggtgggtcgacaccaatctctatctcctcc 
Sal Ga 235 + ggaggagatagagattggtgtcgacccacccaggagcagcc 
Ga-G9-b gccaatatgtacctcctcccgaggacttgcttgaggactactgcagtttgatatgc 
Ga-G9+b gcatatcaaactgcagtagtcctcaagcaagtcctcgggaggaggtacatattggc 
 
AMPV full length copy: insertion of spacer sequence. To increase RT-
nested-PCR amplicon sizes, a spacer was added within the amplified region 
between binding sites for the opposing primer pairs, as shown in Figure 7 (b). A 
section of 216 bp was amplified from the AMPV M2 gene using M2:2xho+ and 
M2-SHxho- primers which added Xho1 sites close to each end. A Sal1 site was 
introduced to the FL copy between G8+A and G5-, using Sal Ga 235 – and Sal Ga 
235 + oligos.  After digestion of the plasmid and 216 bp amplicon with Sal 1 and 
Xho1 respectively, both were ligated together (Figure 2 (c)) in the presence of 
Sal 1 and the ligation mixture was used to transform  Invitrogen STB12 
competent cells. Following colony growth and screening using a junction PCR, 
one was grown, from which modified plasmid was prepared. Prior to further 
development, PCRs using nested oligos G8+A, G9+B and G5- were performed.   
Control Virus Recovery. Virus recovery was attempted as previously 
described (158). Briefly, the modified full length copy and three plasmids 
expressing AMPV N, P and L genes, all with upstream T7 promoter sequences, 
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were used to transfect Vero cells previously infected with a fowlpox 
recombinant virus expressing T7 polymerase (20). The cells were incubated for 
6 days and material serially passaged twice in fresh Vero cells. From the first 
passage onwards, cell sheets were examined daily for cytopathic effects (CPE). 
Freeze thawed lysates were further passaged in fresh Vero monolayers.  
Virus irradiation and storage. The Vero cell lysates containing the 
modified virus were freeze-thawed twice then absorbed onto Whatman no 1 
filter paper. After air-drying, this was microwave irradiated at maximum power 
(900 W) for two minutes using a protocol previously demonstrated to 
inactivate virus, but not inhibit the detection of viral RNA by RT-PCR (71). The 
filter papers were cut into 3 x 0.5 cm pieces and stored in 1.5 ml flip top tubes 
at 4°C. To assess virus inactivation, treated papers were immediately soaked in 
Vero cell culture medium, vortex mixed then resultant liquid was used to 
inoculate Vero cell monolayers.  
Testing of the modified virus as an RT-nested-PCR control. The control 
virus was tested alongside subtype A (UK3B (60) and subtype B virus test 
viruses (Merial Aviffa). The details and sizes of the expected RT and PCR 
products for the newly generated control virus are given in Figure 8. 
Immobilised, microwave irradiated control virus was identically tested as was 
the same material after storage for one year.   
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Figure 8: Outline of the RT-nested-PCR stages and sizes when using the modified control virus and  standard 
test components 
 
 
2.4 RESULTS  
 
 
Modification of AMPV LAH A FL clone. Using the G9+B/G5- primed PCR, 
the modified FL clone yielded a product of the expected size of 360 bp on a 2% 
agarose gel, thereby confirming that the G9+B sequence had been added as 
designed. Following addition and cloning of the Xho1 cut 216 bp spacer region, 
PCR tests using G8+A/G5- and G9+B/G5- primer combinations produced 
products with the expected sizes of  463 and 556 bp respectively, thereby 
confirming that the FL copy had been successfully modified (data not shown). 
Recovery of modified virus. Seven days after transfection of Vero cells 
with the modified cloned FL and support plasmids, material was freeze-thawed. 
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Four days after inoculation of fresh Vero monolayers, CPE typical of AMPV 
infection was readily observed by low power microscopy.   
RT-nested-PCR control of recovered virus. Analysis of RT-nested-PCR 
products on a 2% agarose gel showed bands of 268 bp for subtype A virus, 361 
bp for subtype B virus, no band for the negative control and bands of 463 and 
556 for the inactivated positive control virus. The results are shown in Figure 9. 
Cell culture of microwave irradiated virus. CPE was not observed in 
Vero cell cultures inoculated with liquid collected from soaked microwave 
irradiated material. Equally no CPE was seen after a further passage in fresh 
Vero cells.  
RT-nested-PCR control of microwave irradiated virus. Results were 
identical to those for viable virus (data not shown). 
Stability of microwave irradiated virus. When the RT-nested-PCR was 
performed on material stored for one year at 4oC, results were identical to 
those seen one year earlier (data not shown).  
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Figure 9: 2% agarose gel of the RT-nested-PCR G gene products with templates using UK3B (A), Merial Aviffa (B) 
and modified control virus (PC). Also water control (NC) and  size markers (M) 
 
 
2.5 DISCUSSION 
 
 
RT-nested-PCR is a flexible virus detection technique of similar 
sensitivity to efficient isolation techniques while affording the advantage that 
only the intact targeted RNA is required for positive detections. However, there 
is also greater risk of test positives due to contamination with residual 
environmental nucleic acids, whereas in contrast, infection of culture based 
detection systems with viable remnants of environmental viral contaminants 
would be unlikely. The necessary inclusion of positive control standards in 
detection runs adds to this risk (128) and its relative impact is greater if the 
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majority of  test samples are negative, due to risk of contamination from the 
control virus. Nevertheless, positive control standards are generally included 
because of the need to distinguish between true detection negatives and those 
arising from test system malfunction. The novel control virus made and tested 
in this study removes the need to choose between conflicting demands. As for 
conventional AMPV control standards, the presence of correct bands confirms 
that all stages of the detection system, RNA extraction, reverse transcription 
and PCRs, are functional but in addition, the increased size of amplicons 
immediately identifies instances where sample test positives result from 
contamination with the novel control.  
An alternative to the described strategy might be T7 driven in vitro 
transcripts generated from suitably constructed plasmids. However this would 
have several disadvantages, one of which being that transcripts would not act 
as controls of RNA extraction from virus. Another consideration would be that 
remnants of the plasmid DNA would need to be scrupulously removed 
otherwise its presence would invalidate the check of reverse transcription. 
Finally it is not clear whether stored immobilised naked RNA would share 
similar stability because in the case of the described control virus, the RNA is 
likely to have been stabilised by other viral components including the 
ribonuclear proteins. 
A potential problem with adopting such a live control virus in some 
regions might be its genetically modified nature. However, the microwaved-
irradiated virus was shown to work equally well and Vero cell culture was used 
to confirm that all virus infectivity had been lost. Furthermore, the inactivated 
virus was found to remain fully functional as a control after a year of 
refrigerator storage. Hence a control has been developed which does not 
present any infection risks so can be used safely in all laboratory situations.  
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The control virus described might also find useful application as an 
internal control. In principle the control could be simply added to all test 
unknowns. Both normal and larger control virus induced amplicons would be 
seen for positive samples, while test samples lacking AMPV target RNA would 
generate only the larger amplicons. However before being used in this manner, 
the test would need to be validated to ensure that competition or other 
unforeseen events did not interfere with the function of either sample or 
control RT-nested-PCR tests. This is likely to be an area of further investigation 
in our laboratory.    
The methodology is likely to be similarly useful for preparation of 
positive controls for the many RT-PCR tests used for detection of  other RNA 
viruses, both avian  (38, 85, 204) and non-avian (10, 27, 72). The addition of a 
complete foreign gene to subtype A AMPV has already been demonstrated 
(137) hence it will be a routine matter to similarly add sequence from viruses 
such as those listed, irrespective of their role in host viruses. Again the foreign 
virus sequence would need modification to enable amplicon size differentiation 
but problems of its incorporation into AMPV anywhere within the regions 
coding for the nonessential SH or G genes (158) would not be expected to 
curtail virus replication. Furthermore, while the inserted small RNA sections 
would be highly unlikely to produce hazardous viruses, this risk would be 
entirely eliminated using the described microwave irradiation procedure. This 
would make the approach very suitable for generating controls for frequently 
used RT-PCR tests detecting hazardous viruses, including influenza and HIV.  
The use of the modified virus as a positive control could also find 
application in real time RT-PCR. For detections utilising Taq polymerase 
catalysed hydrolysis of an annealed fluorescent probe, the application is not 
immediately obvious because the probe should bind to equally well to normal 
or larger test amplicons. However the larger size of control virus amplicons 
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would generally result in higher melting temperatures and this difference could 
be detected in suitable real time machines. A similar approach could also be 
taken using sybr green based PCR tests. In both cases, the design of modified 
viruses would need to be directed towards inserting RNA within the test 
amplified regions so as to give the necessary melting temperature differences, 
while not significantly compromising the efficiency of the given RT-PCR test.  
In summary, a modified AMPV has been generated for use as a positive 
control in an established RT-nested PCR which, after microwave inactivation for 
safety considerations and fridge storage for long-term convenience, confirms 
test function at all test stages from initial RNA extraction from virus to final 
visualization of bands on gels. It has the further potential to be used as an 
internal standard and related modifications could yield real time RT-PCR 
applications.  The main application may lie with other RNA viruses, especially 
those presenting a significant safety risk. Insertion of RNA from those viruses 
into AMPV should result in safe controls for a large range of hazardous RNA 
viruses including HIV and influenza. 
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 CHAPTER 3  
AN INVESTIGATION INTO VECTORING PROPERTIES OF 
AVIAN METAPNEUMOVIRUS  
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3.1 ABSTRACT 
 
 
Seven different AMPV cDNAs, each one in a different intergenic 
region, were modified in order to accept and express a reporter gene. A 
cassette was firstly introduced adding a restriction enzyme site, for actual 
genic sequence insertion, and transcriptional start and stop signals, 
essentials for gene transcription. GFP was then inserted in all constructs and 
after viral rescue, seven viruses carrying the reporter gene were obtained. 
Expression was assessed firstly by fluorescence observation under UV 
microscope and later using a specific GFP ELISA, able to quantify the amount 
of protein produced. Viruses were titrated using both CPE endpoints on Vero 
cells and real time RT-PCR, to calculate the amount of protein produced by a 
single infectious viral dose, and sequenced to detect possible mutations 
occurring during viral passages. Results showed AMPV to be able to accept 
and stably express GFP in all the positions. All recombinants were able to 
reach high titers with the only exception of the one expressing GFP between 
N and P. Expression proved to be highest when GFP was inserted near the 3’ 
end (between N and P) as expected according to the transcriptional model 
for non-segmented negative stranded viruses. Surprisingly even the 
recombinant with the insert in the SH-G position showed high production of 
the reporter gene. Conversely GFP levels were very low in the middle 
positions. 
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3.2 INTRODUCTION 
 
 
The development of reverse genetic (RG) techniques for non-
segmented negative stranded (NNS) RNA viruses has been a big step forward 
in viral research. Generation of viruses derived from DNA copies (cDNA) of 
their genome has allowed scientists to study not just the effect of specific 
mutations on viral biology but also to perform major changes such as 
deleting or adding genes (47, 48, 229). Since RG has been established, 
several NNS RNA recombinant viruses expressing foreign genes have been 
constructed in order to develop improved or multivalent vaccines (164, 189). 
These viruses have been shown to be suitable candidate as vectors: (I) they 
do not replicate through DNA intermediates, so integration of the foreign 
gene into the host genome is very unlikely; (II) recombination is extremely 
rare; (III) they have a simple genome organization, involving only 5-11 
proteins and genes are usually not overlapping, making manipulations 
easier; (IV) they grow to high titres and express high levels of proteins; (V) 
they commonly induce strong humoral and cellular immune responses (48, 
189, 229) and (VI) they have been proven to accept and stably express 
foreign genes without mutations incurring over several passages (147, 192). 
Avian metapneumovirus (AMPV) is a member of this order, belonging to the 
family Paramyxoviridae, subfamily Pneumovirinae. It transcripts for 8 
different genes, namely N, P, M, F, M2, SH, G and L (70). AMPV affects 
mainly turkeys and chickens causing respiratory infections and reproductive 
effects on laying birds, such as breeders and laying hens and secondary 
infections exacerbate the effect of the primary virus infection (50). In 2004 
the first RG system was developed for AMPV (158) and since then several 
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studies have investigated the effects of single and multiple mutations or 
even whole gene deletions (23, 44, 92, 133, 158, 163). A few reports have 
shown the possibility to add and express foreign genes in the viral genome 
(92, 136), suggesting the possibility of using AMPV as a vector for a 
multivalent vaccine. However, during the construction of recombinant 
viruses several technical questions might arise regarding for example the 
insertion position of the new gene. Current transcriptional models for NNS 
RNA viruses propose that viral polymerase should enter the genome only at 
position 1 at the 3’ leader end, transcribing all genes obligatorily in a 
sequential and polar manner (from 3’ to 5’). Along the RNA, polymerase 
encounters specific gene start and stop signals. The latter ones seem to 
facilitate the fall off of a certain amount of polymerase molecules from the 
genome, while the rest of them carry on in the transcription process. This 
results in a quantity of polymerases able to move toward 5’ end, which 
gradually decrease at every gene junction. Levels of gene expression are 
then regulated primarily by the position of each gene relative to the 3’ end, 
meaning upstream genes are more easily transcribed than downstream 
genes (233). According to this, it would be preferred to add a foreign gene at 
the proximal 3’ position, as it would result in higher expression of the insert 
and, thinking to a future vaccine use, this might be critical for viral 
immunogenic activity in birds. However a previous study using Vescicular 
stomatitis virus (VSV) has shown that genes added in a very early position 
can be a problem for virus viability (232). 
In order to try to understand, which position is more likely to give 
best expression performances for AMPV without penalizing viability, seven 
different viruses were constructed, expressing green fluorescent protein 
(GFP) in different intergenic regions (IGR). GFP, surrounded by new gene 
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start and new gene stop sequences, was introduced at every IGR in AMPV 
full length cDNAs, which were then rescued according to Naylor et al. (158). 
Recovered viruses were passaged three times on Vero cells and then titrated 
by observing cythopatic effect (CPE) endpoints as an indicator of viral 
viability in vitro. Inserted gene expression was firstly assessed by observing 
the fluorescence under UV microscope and then quantified using a specific 
GFP ELISA. ELISA results were then compared to viral titres in order to 
calculate the protein expression quantity per single infectious dose. 
However, as the previous titration method is based on capacity of the virus 
to infect cells, all viruses were also titrated with real time RT-PCR for a better 
accuracy (184). Real time RT-PCR directly detects viral RNA, revealing the 
presence of viral particles which have a lack of infectivity, but which can still 
transcribe genes (184). This appears critical in avoiding under or over 
estimation of viral titres and then of GFP expression. Specific messenger RNA 
(mRNA) RT-PCRs (23) for every upstream gene to the insertion point were 
also performed in order to evaluate the functional gene stop. Polymerase 
failure in stopping at the signal can lead to the production of dicistronic 
messanger RNA, resulting in a lack of expression of the insert (233).  
 
 
3.3 MATERIALS AND METHODS 
 
 
Standard cassette insertion, allowing gene expression. Seven full 
length AMPV cDNAs of an A derived strain (158) were modified to add a 
cassette in each one of the seven IGR present in the genome. The cassette was 
designed and ordered. It comprised two annealed complementary primers (Cas 
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+ and Cas neg) and included a transcriptional start (GGGACAAGT), a Sal I 
restriction endonuclease site (GTCGAC) and a transcriptional stop 
(AGTCAATAAAAAA) (Figure 10). Xho I restriction endonuclease sites were 
previously inserted in the genome by site-directed mutagenesis (SDM) to allow 
insertion. Ligation of the cassette was performed in the presence of Xho I. 
Primers used for this aim are shown in Table 2. 
 
          
Figure 10: Cassette showing transcriptional start (T start), restriction endonuclease site (Sal1 site) and 
transcriptional stop (T stop). 
 
GFP insertion. GFP gene was amplified using primers GFP ins + and 
GFP ins neg which added XhoI sites to both ends. After Xho I digestion of the 
amplicons and Sal I digestion of the cassetted AMPV cDNAs, these were 
ligated together in the presence of both enzymes. Figure 11 summarizes the 
modifications made in the IGR. After cloning into stb12 cells, colonies 
containing DNA with correct gene orientation and sequence were selected. 
The modified constructs were then sequenced to exclude possible 
mutations, which may have occurred during these processes. Seven cDNAs 
were selected, each one with GFP in different IGR (Figure 12). 
Viral rescue. GFP AMPV cDNAs were rescued as described by Naylor 
et al in 2004. Modified full length copy and four plasmids expressing AMPV 
N, P, M2 and L genes, all with upstream T7 promoter sequences, were used 
to transfect Vero cells previously infected with a fowlpox recombinant virus 
expressing T7 polymerase (20). The transfected cells were incubated for 6 
days and the recombinant viruses were serially passaged in fresh Vero cells.  
52 | P a g e  
 
 
 
Table 2: Oligonucleotide sequences of premises used in the study 
 
Primers Name Primers (5’… 3’) Function
IGR-Xho-NP + CAAATTTGAGTAATTAAAAACTCGAGGGACAAGTAACAATG Insertion XhoI site betw een N and P genes
IGR-Xho-NP neg CATTGTTACTTGTCCCTCGAGTTTTTAATTACTCAAATTTG Insertion XhoI site betw een N and P genes
IGR-Xho-PM + GATCTGTAGTTATGAAAAACTCGAGGGACAAGTCAAAATGGAG Insertion XhoI site betw een P and M genes
IGR-Xho-PM neg CTCCATTTTGACTTGTCCCTCGAGTTTTTCATAACTACAGATC Insertion XhoI site betw een P and M genes
IGR-Xho-FM2 + CAGTTAAGTTATTTAAAACTCGAGGGACAAGTGAAGATGTC Insertion XhoI site betw een F and M2 genes
IGR-Xho-FM2 neg GACATCTTCACTTGTCCCTCGAGTTTTAAATAACTTAACTG Insertion XhoI site betw een F and M2 genes
IGR-Xho-M2SH + GTTAATTAAAACCACTCGAGCTATAAGGCCAATAAAGG Insertion XhoI site betw een M2 and SH genes
IGR-Xho-M2SH neg CCTTTATTGGCCTTATAGCTCGAGTGGTTTTAATTAAC Insertion XhoI site betw een M2 and SH genes
IGR-Xho-SHG + GTATTATTTAATTAAAAAAAACTCGAGGGACAAGTATCTCAATG Insertion XhoI site betw een SH and G genes
IGR-Xho-SHG neg CATTGAGATACTTGTCCCTCGAGTTTTTTTTAATTAAATAATAC Insertion XhoI site betw een SH and G genes
IGR-Xho-GL + GTCTAAAACAATTAAACTCGAGAAAAACAAGGACCAATATG Insertion XhoI site betw een G and L genes
IGR-Xho-GL neg CATATTGGTCCTTGTTTTTCTCGAGTTTAATTGTTTTAGAC Insertion XhoI site betw een G and L genes
MF Xho I + GTTATAGTCAATAAAAAATTCTCGAGGGACAAGTAGGATGGATGTA Insertion XhoI site betw een M and F genes
MF Xho I neg CAGATTCTTACATCCATCCTACTTGTCCCTCGAGAATTTTTTATTG Insertion XhoI site betw een M and F genes
Cas + TCGACGGGACAAGTCGACAGTAATTAAAAAAG Cassette construction
Cas neg TCGACTTTTTTAATTACTGTCGACTTGTCCCG Cassette construction
GFP ins + GGGACCTCGAGTATGGTGAGCAAGGGCGAGGAGC GFP amplif ication
GFP ins neg CCACTCCTCGAGATTTTACTTGTACAGCTCGTCC GFP amplif ication
N1+ CAATATAATGTTGGGCCATG N gene mRNA RT-PCR
P1+ GCAATGATAGGGATGAGA P gene mRNA RT-PCR
M8+ GAAGCTGCAATAAGTGGGGAAG M gene  mRNA RT-PCR
F8+ CCCTGAGGATCAGTTCAATGTTGC F gene mRNA RT-PCR
M2 MID FOR CCAGAGATTCAATGCTTGAAGACCC M2 gene  mRNA RT-PCR
SH70 + GGACAGTGATCAAGTAAAGGTGC SH gene mRNA RT-PCR
G7+ GAAAAGACATTCAGTACATAC  G gene mRNA RT-PCR
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GFP
GFP
Figure 11:  Schematic representation of the strategy used for adding genes to cloned AMPV genome copies. An Xho1 RE 
site, then standardized cassette and finally chosen gene for expression (illustrated by GFP) were added to intergenic 
regions (IGR) between upstream gene transcriptional stops (UT stop) and the downstream gene transcriptional starts (DT 
start). 
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Figure 12: Seven cDNAs were constructed, each one including GFP in a different intergenic position 
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From the first passage onwards, cell sheets were examined daily for 
cytopathic effect (CPE). Freeze-thawed lysate was further passaged three 
times in fresh Vero monolayers. 
GFP expression. As GFP has the capacity to exhibit bright green 
fluorescence when exposed to light in the ultraviolet range, infected cell 
monolayer sheet were observed under UV optical microscope to prove 
foreign protein expression. 
Viral titration. Viruses were titrated using two different methods. 
Titration based on CPE endpoints in Vero cells was performed and titres 
calculated  according to Reed and Muench (183). Real time RT-PCR specific 
for AMPV (41) was also used and the obtained data were compared to AMPV 
standard curves, enabling titres calculation. 
Sequencing. Viruses were sequenced in order to check possible 
mutations occurring particularly in GFP or in the transcriptional cassette 
during serial passages. 
GFP ELISA. Quantification was carried out using a commercial ELISA 
kit (CELL BIOLABS, INC.) for detection of GFP in cell or tissue samples for all 
seven viruses. Protein quantities were determined by comparing resultant 
adsorbance with GFP standards values. Total GFP quantities for each virus 
were then compared to viral titres to calculate the amount of GFP (pg) 
produced by a single viral infectious dose. 
Upstream gene mRNA RT-PCR. mRNAs were amplified using 3’ RACE 
technique described by Sambrook and Russell (188) and adapted to AMPV by 
Brown et al. (23). RT-PCR was performed to generate N gene mRNA in virus 
r1, and mRNA for genes P, M, F, M2, SH, and G in virus r2, r3, r4, r5, r6 and r7 
respectively (23). 
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Statistical Analysis. Data normality was assessed using the 
Kolmogorov Smirnov non parametric test. The one sample T-test was used to 
test if each one of the modified virus titres was statistically different from 
the others considered as a unique population. This analysis was performed 
excluding the most extreme values of the series. The test enabled us to 
understand from a mathematical point of view, if errors occurred during viral 
titrations. The relation between virus titres in Vero cells and between pg of 
GFP per Vero cells infectious dose and pg of GFP per real time RT-PCR 
infectious dose was investigated using the Pearson’s correlation coefficients, 
which appeared the most appropriate test for the purpose. A probability of p 
< 0.01 was considered statistically significant. All statistical analyses were 
performed using SPSS for Windows Rel. 12.0.0. 2003 (SPSS Inc., Chicago - IL). 
 
 
3.4 RESULTS 
 
 
Recombinant GFP AMPVs. First cassettes and then GFP genes were 
successfully inserted in each of the different AMPV cDNAs. Seven 
recombinant viruses, each one expressing GFP in a specific IGR, were rescued 
on Vero cells, all showing typical AMPV cythopathic effect (CPE). CPE was 
diffuse in all cell monolayers, excluding the one infected with r1, where only 
sporadic CPE was observed. 
UV microscopy observation. All recombinants produced strong 
fluorescence when observed under a UV microscope, proving the presence 
of GFP (Figure 13). 
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Figure 13: GFP expression observed under UV microscope by the different recombinants. A negative AMPV control was also performed
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Viral titration. With the only exception of r1, all viruses showed high 
titre levels of between 4 and 5 log10 TCID50 per ml on Vero cells and between 5 
and 6 log10 copies per ml with real time RT-PCR (Table 3). In both methods, the 
titres of r1 were less than 3 log10 per ml, and proved to be significantly lower 
(p<0,01 and p<0,01) than the other viruses. Apart from r1, the results for the 
two titration methods shared high correlation (p<0,01). 
 
Table 3: Viral titres calculated using cell culture or real time RT-PCR 
VIRUS Titrations in Vero cells (log10 TCID50 per ml) Titrations by real time RT-PCR (log10 per ml) 
r1 2,14 2,99 
r2 4,1 5,7 
r3 5 5,55 
r4 4,5 5,34 
r5 4,85 5,35 
r6 4,2 5,04 
r7 4,43 5,13 
 
 
Sequencing. No mutations were detected after 3 passages in any of the 
viruses, proving the high viral stability despite the extra gene insertion. 
GFP ELISA. Figures 14 and 15 show GFP expression in picograms per 
infectious dose of virus, using Vero cell and real time RT-PCR titrations 
respectively. GFP expression was highest when GFP was inserted near the 3’ 
(r1) as expected (p<0,01 and p<0,01), but surprisingly even r6 showed a high 
expression of the reporter gene (p<0,01 and p<0,01). GFP levels appeared 
instead to be very low in the middle positions (r3, r4, r5) and at the very end 
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(r7). The very high r2 GFP level in Figure 14 compared to the corresponding one 
in Figure 15 suggests a strong underestimation of the real viral titres by Vero 
cell titration. This is also confirmed by looking at the statistical correlation 
between GFP Vero cells and GFP real time RT-PCR when r2 values are not 
considered (Figure 16). 
 
 
Figure 14: Amount of GFP protein (pg) per single infectious dose based on Vero cell titration 
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Figure 15: Amount of GFP protein (pg) per single copy based on real time RT-PCR titration 
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Figure 16:  Comparison of GFP (pg) expressed by one infectious unit estimated by CPE in Vero cells with that 
estimated using real time RT-PCR. The Graphs show the correlation found between viral titers (A and B) and GFP 
expression (C and D), including (A and C) or not including (B and D) r2 values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62 | P a g e  
 
 
mRNA RT-PCR. All upstream gene stop signals were capable of stopping 
polymerase transcription as showed by the strong PCR bands visible on agarose 
gel (Figure 17). 
 
 
 
Figure 17: Specific upstream mRNA RT-PCRs bands viewed on agarose gel 
 
 
3.5 DISCUSSION 
 
 
Seven different AMPV cDNAs were modified, each one in a different 
IGR, in order to accept and express the GFP reporter gene. A cassette was firstly 
introduced adding a restriction enzyme site, for actual genic sequence insertion, 
and transcriptional start and stop signals, essentials for gene transcription. GFP 
was then inserted in all constructs and, after viral rescue, seven viruses carrying 
the reporter gene were obtained. Expression was assessed firstly by the 
presence of fluorescence under a UV microscope and later using a specific GFP 
           r1      r2       r3      r4      r5      r6      r7 
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ELISA, able to quantify the amount of protein produced. Viruses were titrated 
using both CPE endpoints on Vero cells and real time RT-PCR, to calculate the 
amount of protein produced by a single infectious viral dose, and sequenced to 
detect possible occurrence of mutations during viral passages. 
This study demonstrated the capacity of AMPV to accept and tolerate 
insertions in all the IGRs. The insertion process appeared to be very easy and 
both transcriptional signals present in the cassette proved to be effective for 
gene transcription, suggesting that the same system could be used for adding 
other genes, expressing, for example, foreign viral proteins. After rescue, CPE 
was seen in Vero cells infected with all recombinants and evidence of GFP was 
confirmed by observing strong fluorescence in all recombinants. Recombinant 
viruses were passaged three times and titrated in Vero cells and obtained titres 
were interpreted as an indicator of viral viability in vitro. All viruses, except r1, 
replicated in Vero cells to high titres (between 4 and 5 log10 per ml), with r3 
producing the highest titre. The insertion of GFP between N and P significantly 
reduced the titre of r1 to less than 3 log10 per ml, which was statistically 
different from the others. These data are similar to those reported in the 
construction of VSV recombinants (232). N and P are in fact two essential 
components of the ribonuclear complex (RNP), which is critical for genome 
replication and transcription. Studies on VSV have shown the molar ratio 
between these two proteins to be critical for RNP functionality and an insertion 
in that position seems to significantly alter this ratio, causing reduced virus 
production (106, 174) and this might explain the low titre.  
Although all viruses showed the capacity to carry and express GFP, 
quantification of this expression was performed by ELISA and results were 
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compared to the total amount of virus in order to assess the actual expressing 
efficiency per single infectious viral dose. AMPV is a NNS RNA virus and in such 
viruses, gene transcription and expression are regulated by gene position with 
respect to the polymerase single entry point at 3’ end. In this type of virus 3’ 
proximal genes appear to be the most transcribed while the distal 5’ ones are 
the least, with a sequential and gradual decrease at every gene junction of 20 – 
30 % in terms of transcription rate, due to polymerase dissociation (108, 233). 
Therefore, we expected to detect the best GFP expression efficiency in r1 and 
least in r7, with the other recombinants varying GFP expression according to 
the distance of the inserted gene from the 3’ end. 
For a correct efficiency estimate, it was essential to define the exact 
viral titre, as insertion of foreign sequences in certain positions can severely 
affect viral biology (232). Poor replication and viability would result in fewer 
viral particles being produced and, as consequence, in less total proteins 
expressed leading to an underestimation of this efficiency. On the other hand, 
an undercalculated virus amount would produce a greater total amount of 
proteins, causing an overestimation. As already explained above, viruses were 
titrated firstly on Vero cells and secondly, for an improved accuracy, real time 
RT-PCR was performed. One method relies on the viral capacity to infect Vero 
cell monolayers and the other detects the viral genome quantity by PCR. While 
the first titrates viruses by assessing the presence of infective virus with ten-
fold dilutions and detects the end point of particles able to cause CPE, the latter 
detects the presence of viral RNAs, including those encapsidated in virions, 
which, for different reasons, do not cause CPE, but are at least potentially able 
to transcribe and express genes.  
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Real time RT-PCR gave higher titres with values between 5 and 6 log10 
copies per ml, compared to the 4 and 5 log10 TCID50 reached on Vero cells. This 
is easily explained considering the different scientific principles standing behind 
each method. However, statistical analysis showed a good correlation when 
comparing both titres of each recombinant, proving the accuracy of our 
estimate. Only r2 showed a large discrepancy between the two values. This 
virus had GFP inserted between P and M and it might be speculated that an 
insertion in that position could decrease the synthesis of M protein, which 
appears to be critical for viral assembly (171, 210). This would not affect the 
amount of RNA produced, as showed by the real time RT-PCR, but reduces in 
less infectious virions and lowers CPE endpoints. 
GFP ELISA results were compared to both viral titres to calculate the 
expression efficiency per single infectious dose. As shown in Figures 14 and 15, 
trends were identical for both methods, with the only exception of r2, where, as 
explained above, virus titres in Vero cells was probably underestimated, gaving 
an overrated GFP expression per dose. The above speculation was suggested 
even by statistical analysis as seen in Figure 16. Excluding for this reason r2, r1 
showed the highest level of expression efficiency, followed by r6 and r7, while 
r3, r4 and r5 appeared to have a very poor expression. Surprisingly, these 
findings do not match with the current transcriptional model for NNS RNA 
viruses. Although r1 was expected to produce the greatest amount of GFP per 
infectious dose and actually did, however it does not seem clear why r3, r4 and 
r5 showed such low levels. Furthermore this theory does not explain either 
why, r6 and r7 are respectively the second and the third viruses for expression 
efficiency. It might be speculated that AMPV does not respect the established 
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model, and perhaps the polymerase might entry the genome in an other 
position, for example prior to SH-G junction. This might clarify the r6 and r7 
results, but would not totally explain r3, r4 and r5 GFP levels.  
A different explanation, which complies with polymerase single entry 
theory, might elucidate the trend observed in Figures 14 and 15. Looking just at 
r1, r6 and r7 values, it is possible to recognize a decreasing gradient, where r1 is 
the highest point and r7 the lowest. r3, r4 and r5 low levels might be explained 
by the presence of a non-effective stop signal of the previous gene. In that case 
the majority of the polymerase molecules would read through GFP, transcribing 
a high amount of dicistronic messenger RNA. Viral mRNA including two genes 
leads at ribosomial stage to the synthesis only of the protein encoded by the 
first one, considerably reducing the amount of GFP. For this reason, the 
upstream gene mRNA RT-PCR was performed for all recombinants. Good bands 
were seen for all constructs proving the functionality of the stop signals. 
However as proven by the fluorescence observation, GFP expression has been 
seen with all viruses, meaning there could be a mixed population of GFP 
dicistronic and monocistronic mRNA. Different percentages of dicistronic and 
monocistronic GFP messenger might than explain the differences found in 
protein values per dose among recombinants. However to be able to prove 
that, other techniques such as Northern Blot or mRNA real time PCR should be 
employed.  
Alternatively instability problems of the viruses, related to the insertion, 
might have explained this picture, but sequence analysis showed no mutations, 
proving the high stability of recombinants derived by NNS RNA viruses, as 
reported by previous studies (192). 
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In conclusion, seven different AMPV recombinants expressing GFP in 
different genome position were constructed and GFP expression efficiency was 
assessed by ELISA results compared to viral titres. The virus with the insertion 
between N and P (r1) proved to produce the highest quantity of reporter 
protein per infectious viral dose, followed by the one having GFP between SH 
and G (r6). However, as r1 showed a very low viral viability in vitro, r6 proved to 
be a better vector virus, resulting in SH and G to be the best likely position for 
insertion of extra genes. Future work is essential to confirm these findings in 
chickens, testing if the outcomes found in vitro have effects on animal models, 
especially in terms of immunological induction. This appears to be crucial for 
the future development of recombinant vaccines using AMPV. 
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 CHAPTER 4  
AVIAN METAPNEUMOVIRUSES EXPRESSING INFECTIOUS 
BRONCHITIS VIRUS GENES ARE STABLE AND INDUCE 
PARTIAL PROTECTION 
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4.1 ABSTRACT 
 
 
This study investigates the ability of subtype A of Avian metapneumovirus 
(AMPV) to accept foreign genes and be used as a vector for delivery of genes from 
Infectious bronchitis virus (IBV) QX to chickens. Initially the green fluorescent 
protein (GFP) gene was added to AMPV at all gene junctions in conjunction with 
the development of cassetted full length DNA AMPV copies. After recombinant 
virus had been recovered by reverse genetics, GFP positions supporting gene 
expression while maintaining virus viability in vitro, were determined. 
Subsequently, either S1 or nucleocapsid (N) genes of IBV were positioned 
between AMPV M and F genes, while later a bivalent recombinant was prepared 
by inserting S1 and N at AMPV MF and GL junctions respectively. 
Immunofluorescent antibody staining showed that all recombinants expressed the 
inserted IBV genes in vitro and all recombinant viruses were found to be highly 
stable during serial passage.  Eyedrop inoculation of chickens with some AMPV-
IBV recombinants at one-day-old induced protection against virulent IBV QX 
challenge 3 weeks later, as assessed by greater motility of tracheal cilia from 
chickens receiving the recombinants. Nonetheless evidence of AMPV/IBV 
seroconversion, or the replication of recombinant viruses in trachea, were largely 
absent.  
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4.2 INTRODUCTION 
 
 
Avian metapneumovirus (AMPV) is a major endemic respiratory pathogen 
of global domestic poultry with the exception of Australasia (14), with most severe 
disease occurring in turkeys, but also causing respiratory disease and reduced egg 
production in chickens. In both species, secondary infections can play an 
important role in exacerbating the disease (50). AMPV is an enveloped negative 
sense single stranded RNA virus belonging to the subfamily Pneumovirinae, genus 
Metapneumovirus (178) and four subtypes have been recognized (A, B, C and D) 
based on nucleotide sequence analysis (12, 122, 193). The genome comprises 8 
genes with most subtypes having a genome size close to 13.5 kb (70).  
The construction of reverse genetics (RG) systems for subtypes A and C has 
allowed those AMPV genomes to be rationally modified (92, 158). To date RG has 
produced viruses with deletions, gene modifications and reporter gene insertions 
(23, 92, 133, 163). Some studies have also given an indication of replicative ability 
of recombinants in vivo (133, 163) but there have been no reports concerning the 
genome’s ability to accept extra viral genes, or the genetic stability of such 
recombinant viruses. In the current study, two genes from infectious bronchitis 
virus (IBV) were inserted into the AMPV genome.  IBV is a major pathogen of 
chickens worldwide, which like AMPV, primarily infects the respiratory tract, while 
the former, also has the ability to infect the kidneys, intestine and reproductive 
system (35). Epidemiology is characterized by the frequent emergence of new 
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variants, of which some have major disease significance due to being able to avoid 
protection induced by prevailing vaccines, in combination with an ability to cause 
pathogenic effects. An example in the late 1980s/early 1990s was the emergence 
of the 793B/4-91/CR88 genotype (28, 59) which caused notable disease on farms 
in Europe with associated economic losses and led to the generation of new 
vaccines. More recently this trend has been manifested by the emergence of the 
QX genotype (238), and genes from this genotype were utilized in the current 
study.  
The major viral surface protein is spike, which is coded by a single gene 
producing a precursor protein S0, which is cleaved into S1 and S2. The former is 
outermost on the virus and influential in IBV antigenicity (35). The internal 
nucleocapsid (N) protein can also induce protective immunity (199, 242) and that 
immunity has been shown to involve both T and B lymphocyte epitopes (199, 
241). In the present study three AMPV genomes were modified to accept the IBV 
QX genes. Virus A was a German field isolate subsequently passaged in Vero cells 
(158), which was found to be avirulent in turkeys (163). Virus A vF was an F #8544 
gene modification of A and found to dramatically increase induced immunity in 
turkeys while inducing a very minor increase in  virulence (163). Virus 309/04 was 
a virulent field isolate derived from an unrelated subtype A vaccine (30). Hence for 
the study, three genome types from viruses with a spectrum of virulence were 
employed.  
Prior to introduction of IBV QX S1 or N genes, a cloning site flanked by a 
transcription start and stop sequence was added to the intergenic regions of the 
full length (FL) DNA genome copies (cDNAs) of AMPV. Initially GFP was added to 
these sites and recombinant viruses were recovered, both as proof of principle 
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and to aid future vaccine optimization; then AMPV-S1-IBV and AMPV-N-IBV 
recombinant viruses were similarly constructed. Two versions of the S1 gene of 
IBV were inserted and used because sequencing of the selected QX genotype 
revealed that this gene comprises two sequence populations present, with one 
containing a 15 nucleotide deletion.    
Recombinant viruses were used to inoculate chickens to determine their 
ability to induce protective immunity against IBV challenge in two different 
experiments. Inoculation of chickens with most IBV field strains leads to infection 
of and damage to the tracheal ciliated epithelium (65). This loss of  cilia and/or 
motility is readily observed by low power microscopy (37) and induced protection 
is now considered to be most reliably confirmed by the maintenance of motility 
following virulent challenge (78) as was taken into account in European 
Pharmacopoeia, IBV vaccine monographs.  To assess replication of AMPV-IBV 
recombinants prior to challenge, real time RT PCR was performed on material 
from choanal swabs and specific antibody responses to IBV and AMPV were 
measured by ELISA and hemaglutination inhibition (HI). 
      
 
4.3 MATERIALS AND METHODS 
 
 
Addition of  GFP to AMPV.  Using site directed mutagenesis, seven 
versions of a virus A (163) FL cDNA were made. A Xho1 restriction endonuclease 
(RE) site was added between each gene in the untranslated region, following the 
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leader proximal gene stop signal and prior to the downstream gene start signal. A 
cloning cassette flanked by cut Sal 1 RE sites, allowing foreign gene insertion and 
transciption, was ligated into each cut Xho1 RE site of the seven FLs.  After cloning 
into STB12 cells (Invitrogen), the seven FLs were cut with Sal 1. GFP genes  flanked 
by Xho1 sites were produced by high fidelity PCR  using primers GFP ins + and GFP 
ins neg (Table 4) and these were added to the seven A varaint FL cDNAs by 
ligation.  After cloning, colonies containing DNA of correct orientation and 
sequence were selected by PCR and sequencing. FLs containing GFP were then 
recovered by RG (158). Expression of the reporter gene was assessed by 
fluorescence microscopy. Virus viability was evaluated as maximum titers 
obtained in Vero cell monolayer titrations following three passages. The insertion 
process is outlined in Figure 18. 
 
 
Figure 18: Schematic representation of the strategy used for adding genes to cloned AMPV genome
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Table 4: Oligonucleotide sequences of primers used in this work 
 Name Primers (5’… 3’) Function 
1 GFP ins + GGGACCTCGAGTATGGTGAGCAAGGGCGAGGAGC GFP amplification adding XhoI sites 
2 GFP ins neg CCACTCCTCGAGATTTTACTTGTACAGCTCGTCC GFP amplification adding XhoI sites 
3 N  all b neg ACTAATGAGAATCACAATAATAAAAAGCACAG N RT and PCR amplification 
4 N 200 + GCAGCATGGATACTGGAGACG N sequencing 
5 N 300 neg GGTCAGCGGCTGGTCCTGTTCC N sequencing 
6 N 560 + GGTTCACGTGGTCGTAGGAG N sequencing 
7 N 750 + CCAGGTTATAGAGTAGATCAAGTATTTGGC N sequencing 
8 N 920 + CTGTGGTGCCTAGAGATGACC N primer for mRNA PCR 
9 N all + CCAAGGGAAAACTTGTGAGGAACAC N PCR amplification 
10 N start xho + GGAACACTATTATAATAACAATCCTCGAGCATGGCAAGCAGTAAGG N amplification adding sticky ends 
11 N stop xho neg TGTAGCAAGTCCTTACTCGAGTCAAAGTTCATTTTCACCAAG N amplification adding sticky ends 
12 QX 1210 neg ACATTCAAAATTCATGCTTAA Diagnostic RT-PCR for QX IBV 
13 QX 860 + TGTTAATACTACTCTGGCG Diagnostic RT-PCR for QX IBV 
14 QX S1 1050 + GGTTTAATTCCTTGTCAGTTTCTCTTACTTATGG S1 sequencing 
15 QX S1 1380 + GCTGCTAATTTTAGTTATTTAGCAGATGGTGG S1 sequencing 
16 QX S1 270 neg CCTGAAGAGGTGCTGTCATAGC S1 sequencing 
17 QX S1 400 + GGCATGATTCCACGTGATCATATTCG S1 sequencing 
18 QX S1 550 neg CAGTAGTTTTGTTGGAAGTAAAAACAAGATCACC S1 sequencing 
19 QX S1 end neg CGAACCATCTGGTTCAATACAAAATCTGC S1 PCR amplification 
20 QX S1 start + CCAGTTGTGAATTTGAAGAAAGAACAAAAGACCGACTTAG S1 PCR amplification 
21 RT QX S1 neg CATCTTTAACGAACCATCTGG S1 RT amplification 
22 S1 1380 + GCTGCTAATTTTAGTTATTTAGCAGATGGTGG S1 primer for mRNA PCR 
23 S1 start xho + GGTAAATTATTGCTCGAGGATGTTGGTGAAGTCACTGTTTTTAGTG S1 amplification adding XhoI sites 
24 S1 stop xho neg GTTACGTTTTGCTCGAGTTAACGCCTACGACGATGTGAGCTATTGG S1 amplification adding XhoI sites 
25 SX 3 + TAATACTGGYAATTTTTCAGA S1 sequencing 
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Analysis of IBV QX genes prior to insertion into AMPV. An IBV QX virus 
isolated in Germany was grown in eggs, titrated in tracheal organ cultures (TOC) 
and stored in aliquots at -80oC. As the viral RNA sequence was unknown, a range 
of IBV genotype sequences were aligned to identify conserved regions within, and 
flanking, S1 and N genes. These were used to design RT-PCR and sequencing 
primers, as detailed in Table 4. Gene amplification and sequencing revealed the 
presence of two S1 populations, one of which had a deletion of 15 nucleotides. 
Table 5 summarizes the differences found. 
 
Table 5: RNA and predicted amino acid differences between the two S1populations. 
Position 
Full S1 Deleted S1 
Nucleotides AA Nucleotides AA 
8 U V G G 
58-75 UUG UUU GAU UCU GAU AAU LFDSDN UAU Y 
806 C T U I 
1181 U M G R 
 
Predictive computational comparison of S1 populations. The S1 gene 
containing the 15 nucleotide deletion was compared to the intact gene. The 
Protean program of the DNASTAR multiple program package (Lasergene Inc., USA) 
was used to estimate physicochemical properties, composition of the proteins and 
prediction of secondary structures. Order–disorder predictions were obtained 
using the VL-XT predictor on the PONDR server (185). Prediction of 
immunodominant helper T-lymphocyte antigenic sites from primary sequence 
data was carried out by analysing the occurrence of amphipathic fragments using 
the AMPHI algorithm (141). For all analyses, the predictive algorithms had been 
previously shown to be correct in more than 75% of cases.  
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S1 and N IBV amplification for insertion. For gene insertion, Xho I RE sites 
were added to S1 and N gene extremities during RT-PCR amplification by use of 
modifying primers S1 start xho +, S1 stop xho neg, N start xho + and N stop xho 
neg (Table 4).    
IBV gene insertion into AMPV cDNAs.  IBV genes were inserted into 
cloned FL A with the cassette at the MF intergenic region, as well as into 
identically modified FL A vF (163) or FL 309/04 (30). For insertion of a second 
gene, the cloning cassette was additionally added between G and L genes. After 
cloning into STB12 cells, seven recombinant cDNAs were produced as detailed in 
Table 6. 
 
Table 6: Summary of the constructed recombinant cloned FL cDNAs 
Clone name Source virus IBV QX insert Intergenic region  
A del S1 MF A Deleted S1 MF 
A full S1 MF A Full S1 MF 
A vF del S1 MF A vF Deleted S1 MF 
A vF full S1 MF A vF Full S1 MF 
A vF N MF A vF N MF 
A vF full S1 MF + N GL A vF Full S1+ N MF + GL 
309 full S1 MF 309/04 Full S1 MF 
 
Recovery of virus. IBV recombinant viruses were rescued using the 
modified plasmids as previously described and subsequently passaged in Vero 
cells to produce sufficient virus for protection studies. Viruses were titrated in 48 
well plates containing Vero cell monolayers;  cytopathic effect end points were 
78 | P a g e  
 
observed using low power microscopy and titers were calculated (183). Viruses 
were aliquoted in 1.5 ml screw top tubes and frozen at -80oC. 
S1 and N gene messenger RNA RT-PCRs. Specific mRNA RT PCRs (23) were 
used to verify the transcription of inserted genes. Messenger RNA was amplified 
using a previously reported protocol (23) except that primers within reading 
frames were substituted by  S1 1380+ and N 920+ for S1 and N genes respectively 
(Table 4).   
Expression of inserted genes. S1 and N protein expression were assessed 
using immunofluorescence (IF) techniques on AMPV recombinant infected Vero 
cells. A polyclonal chicken antiserum (GD) anti QX was used to evaluate S1 
expression while this was substituted by a monoclonal mouse antibody (Biozol) for 
the N gene. Suitable FITC conjugated anti chicken/mouse antibodies were used 
according to manufacturers’ protocols to enable visualization of specific S1/N 
proteins.  
Chickens experiment 1. Approximately 70 one-day-old SPF chickens were 
assigned to seven groups of ten. In groups one to four, birds were inoculated by 
eyedrop with 4 log10 TCID50  A full S1 MF , A vF full S1 MF, A del S1 MF and A vF del S1 MF  
respectively. The AMPV control group was inoculated with A vF. The remaining 
positive and negative control groups were inoculated with sterile water. At 21 
days post vaccination (dpv), all birds, except the negative controls, were 
challenged with 4 log10 TCID50 QX IBV strain. For sampling, half the chickens in 
each group were humanely culled at 4 days post challenge (dpc) and the 
remainder at 6 dpc. 
Chickens experiment 2. Approximately 60 one-day-old SPF chickens were 
assigned to six groups of ten birds, four of which were inoculated with 4 log10 
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TCID50 of viruses 309 full S1 MF, A vF full S1 MF + N GL, A vF N MF  and A vF full S1 MF virus by 
eyedrop. The remaining groups acted as controls and were inoculated with sterile 
water.  At 21 dpv, all the birds, except the negative controls, were challenged with 
4 log10 TCID50 of IBV QX. In each group, birds were humanely killed five at 4 dpc 
and five at 6 dpc. 
Clinical signs. Birds were observed daily for clinical signs both after 
vaccination and after IBV challenge. 
Serology. Chickens from each group were bled at 18 dpv for IBV and AMPV 
serology. Sera from birds which received S1 recombinant AMPVs were tested 
using an IBV QX HI test, while sera from birds receiving either recombinants 
containing the N gene were tested for anti IBV antibodies by HI and ELISA 
(Biochek). AMPV ELISA (IDEXX) was performed on all sera. 
Assessment of replication of recombinants by AMPV real time RT-PCR.  
Ten choanal swabs were collected from all groups at 3, 6 and 9 days after 
vaccination for specific subtype A AMPV real time RT-PCR (40) to assess 
recombinant replication. 
Determination of tracheal cilial activity. At 4 and 6 dpc in both chicken 
experiments, tracheas were collected and cut into 1 mm transverse sections. For 
each trachea, ten sections were collected (three upper, four middle and three 
lower) and examined under low power microscopy to determine activity of cilia. 
Each section was designated as either containing beating cilia or beating being 
entirely absent. 
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Statistical analysis. Statistical analyses were performed for ciliar motility 
results using the Chi-square test. A p value < 0.05 was considered statistically 
significant. 
 
4.4 RESULTS 
 
 
Recombinant AMPV GFP construction. GFP was added to modified FL 
AMPV copies and viruses were recovered in the reverse genetic system. Maximum 
TCID50 titres per ml of Vero cell lysate achievable following three Vero cells 
passages were generally lower near to the virus leader, then increased; hence 
with GFP at the NP position the titre was 2.1 log TCID50 while in all other positions 
it exceeded 4.0 log TCID50 with the highest being for the MF position which gave a 
titre of 5.0 log TCID50.  Strong fluorescence was observed when infected Vero cell 
monolayers were viewed by UV microscopy for all constructs. Figure 19 shows the 
fluorescence for the GFP MF recombinant. 
 
 
 
 
Figure 19: Vero cell monolayer infected with virus expressing GFP 
between MF viewed under white (left) and ultraviolet illumination 
(right). 
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Computational analysis. Protean analysis of S1 proteins showed both 
clones shared the same physicochemical properties and similarly PONDR 
predicted no differences to the disordered region. Furthermore the Protean suite 
predicted the proportion of alpha helix to remain constant but not for beta 
pleated sheets where a difference was evident at the beginning of the two 
proteins. The AMPHI program predicted a T cell epitope present only in the 
complete S1 protein, at amino acid positions 15-19. However S1 containing the 
deletion possessed two additional predicted T cell epitope regions (amino acid 
positions 264-268 and 383-388). 
IBV recombinant AMPV construction.  AMPV FL cDNAs containing IBV 
genes were constructed which led to virus recovery as confirmed by cytopathic 
effect typical of AMPV on Vero cell monolayers. Viruses were sequenced in order 
to exclude the occurrence of mutations during the three passages. RT-PCR of virus 
mRNAs confirmed transcription of the inserted IBV genes (Figure 20). Expression 
of IBV proteins was confirmed in all recombinant viruses by IF as shown in Figure 
21. 
 
 
 
 
Figure 20: PCR products of 7 AMPV-IBV recombinants using primers for the S1 and N genes of IBV. Specific 
messenger RNA RT-PCRs for S1 are showed in lanes from 1 to 7 while N gene ones in lanes from 8 to 10. 
Viruses tested : 1 - 309
 full S1 MF
, 2 - A vF 
full S1 MF
, 3 - A vF 
full S1 MF + N GL
, 4 - A vF 
del S1 MF
, 5 - A
 full S1 MF
, 6 - A 
del S1 MF
, 
7 - S1 negative AMPV control, 8 - A vF
 N MF
 and  9 - A vF 
full S1 MF + N GL
. Lane 10 - negative AMPV control. 
600 bp 
310 bp 
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Figure 21: Microscopy of VERO cells infected with 7 AMPV-IBV recombinants and negative controls. Top A: 
white light illumination; B: Immunofluorescence using FITCH conjugated specific antibodies. Viruses 1 to 3 
used IBV N monoclonal serum and 4 to 10 used IBV polyclonal chicken serum 
A 
B 
A 
B B 
A 
A A A 
A A A A 
B B B 
B B B B 
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Serology. In general IBV and AMPV antibody responses were not detected 
in either chickens experiments, either by HI or ELISA (Table 7). For IBV in 
Experiment 1, a single bird in group A vF del S1 MF and two birds in group A vF full S1 MF 
had detectably seroconverted by HI. For AMPV ELISA serology, two 
seroconversions were detected in the A vF control group (Experiment 1) and three 
in the 309 full S1 MF group (Experiment 2). 
AMPV real time RT-PCR. Real time RT-PCR showed minimal replication for 
all AMPV recombinants with the exception of 309 full S1 MF, which was replicated in 
most birds (Table 7). 
Tracheal motility following challenge. The percentages of rings showing 
cilial activity are given in Table 7. At day 4, sections from all birds challenged with 
IBV were ciliostatic.  At day 6, some sections from birds previously inoculated with 
AMPV QX recombinants showed recovered cilial motility. Stronger tracheal 
recovery was observed in those birds given A vF full S1 MF + N GL, followed by A vF N MF 
with the least seen in A vF viruses, which express only the S1 gene. There were no 
noticeable differences between recombinant AMPVs expressing the full and the 
deleted S1. When comparing AMPV vectors with identically positioned inserts, 
recombinant vector A led to greater cilial recovery than recombinant of either 
309/04 vector or vector A vF. 
Statistical analysis. Significant p values, calculated comparing each group 
to the respective positive control, were found only for birds vaccinated with A full S1 
MF (p = 0.0002), A del S1 MF (p = 0.0008), A vF full S1 + N GL (p = 0.00001) and A vF N MF (p = 
0.0002). Analysis between these four groups did not reveal any significant 
differences.  
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Table 7: Effects of vaccination with 7 AMPV-IBV recombinants on virus replication, antibody response to IBV and AMPV and on % TOC beating after 
challenge with IBV. 
 Groups AMPV real time RT PCR 
(dpv1) 
Serology  (18 dpv1) % TOC beating 
(dpc2) 
AMPV IBV 
 
 
 
 
Experiment 1 
 Day 3 Day 6 Day 9 ELISA HI ELISA Day 4 Day 6 
A del S1 MF 4/10 0/10 0/10 0/10 0/10 n.d.* 0 20 
A full S1 MF 0/10 0/10 0/10 0/10 0/10 n.d.* 0 24 
A vF del S1 MF 0/10 0/10 1/10 0/10 1/10 n.d.* 0 0 
A vF full S1 MF 0/10 0/10 0/10 0/10 2/10 n.d.* 0 0 
A vF 0/10 0/10 5/10 2/10 0/10 n.d.* 0 0 
C + 0/10 0/10 0/10 0/10 0/10 n.d.* 0 0 
C - 0/10 0/10 0/10 0/10 0/10 n.d.* 100 98 
 
 
 
Experiment 
2 
A vF N MF 0/10 0/10 0/10 0/10 0/10 0/10 0 32 
A vF full S1 MF + N GL 0/10 0/10 0/10 0/10 0/10 0/10 0 40 
309 full S1 MF 6/10 8/10 6/10 3/10 0/10 0/10 0 8 
A vF full S1 MF 0/10 1/10 1/10 0/10 0/10 0/10 0 2 
C + 0/10 0/10 0/10 0/10 0/10 0/10 0 4 
C - 0/10 0/10 0/10 0/10 0/10 0/10 100 100 
1 days post vaccination 
2 days post challenge 
* not done  
C+ and C-: respectively non vaccinated challenged animals and non vaccinated non challenged birds 
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Clinical signs and gross lesions. No symptoms were detected after 
vaccination in both experiments. In Experiment 1, clinical signs were observed 
in three birds at 6 dpc. One bird in the positive control group and two birds in 
the A vF control group displayed severe depression. Birds showed lethargy, 
ruffled feathers and were not responding to major external stimuli and were 
humanly culled. Gross kidney lesions, typical of QX IBV infection, were detected 
at post-mortem examination in the same birds (Figure 22). No symptoms were 
seen in Experiment 2.  
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Comparison of gross lesions in kidneys detected in 1 bird from positive 
control (A) and 2 birds from AMPV control (B and C) groups, compared to a normal 
kidney from the negative control group (D), after challenge with QX IBV. 
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4.5 DISCUSSION 
 
Stable recombinant AMPV viruses carrying GFP and IBV genes were 
generated, which were also demonstrated to express those inserted genes.  IBV 
genes were inserted between the M and F genes of AMPV because insertion of 
the GFP gene in that position gave the most viable recombinant virus. When 
such IBV recombinants were used to inoculate one-day-old chickens, they 
induced IBV protection in the trachea. However serology and virus detection by 
real time RT PCR prior to challenge indicated that recombinant virus replication 
was generally very poor, and surprisingly, those replicating least well in the 
upper respiratory tract of chickens, induced most protection: hence IBV 
recombinants with AMPV virus A protected better compared to AMPV 309/04 
IBV recombinant which induced no detectable protection. Despite computer 
analysis predicting differences of T cell epitopes between S1 populations with 
respect to the 15 nucleotide deletion, no differences were observed in terms of 
induced protection. 
The primary site of both AMPV and IBV replication is the upper 
respiratory tract, hence an AMPV-IBV recombinant might be considered ideal 
for inducing IBV protection in chickens. For effective protection against IBV, the 
recombinant would be expected to be able to grow in those tissues and it 
appears possible that the very low level of replication observed in this study led 
directly to the less than optimal protection induced. An AMPV strain replicating 
better in chickens might yield more favourable results. Growing field evidence 
worldwide, gained by commercial farmers and vaccine companies, is indicating 
that subtype B viruses are more able to infect commercial chickens than the 
subtype A viruses used in the current study. However to date, there have been 
no reports of studies testing the relative ability of subtype A and B viruses to 
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replicate in commercial birds in experimental conditions. Once a subtype B RG 
system becomes available, it will be possible to test this assertion in parallel to 
the testing of subtype B virus recombinants. However, caution should be 
exercised in predicting likely outcomes because the A based recombinant 
AMPVs in the current study induced the best protection while not significantly 
replicating in the upper respiratory tract. In contrast, the AMPV recombinant 
based on isolate 309/04 replicated better but failed to induce detectable 
protection. If further recombinants are found which also induce protection 
without significant respiratory tract replication, it will become necessary to 
investigate whether virus replication occurs at another site or alternatively 
whether protection is induced by a so far unrecognized mechanisms.  There is 
already some evidence that AMPV replication in the respiratory tract does not 
imply induction of AMPV protection (163) as well as the finding that AMPV 
protection following live vaccination does not require initial replication in the 
trachea (159).  Furthermore AMPV vaccination can lead to apparent protection 
without seroconversion (62, 236). 
For the first time, AMPV recombinants are reported carrying foreign 
viral genes. Previously AMPVs have been shown to be highly stable both in cell 
culture and during natural passage (30) as has also been reported for other 
members of the Mononegavirales such as vesicular stomatitis and rabies 
viruses (146, 191). This contrasts with single strand positive sense viruses such 
as IBV and feline calicivirus where even a few passages readily results in 
consensus sequence mutations (35, 180). In the current study it was further 
shown that a recombinant AMPV genome containing IBV S1 and N genes, 
totaling approximately 3000 extra nucleotides, was entirely stable with respect 
to those inserted genes, even though their sequences would be expected to be 
irrelevant to virus function and hence their random mutation would not be 
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expected to adversely affect virus viability.  Furthermore the presence of those 
inserted genes did not appreciably reduce virus viability, so long as they were 
distanced from the leader.  It is likely that placement closer to the leader 
reduced transcription rates of genes required in large quantities to enable 
optimal virus replication, such as the nucleocapsid and phosphoprotein genes 
(232). 
The unproblematic construction of AMPV recombinant viruses suggests 
that it would be possible to generate a range of similar viruses with a view to 
either further RG studies or in order to construct a range of candidate vaccines 
for protection studies.  Regarding the latter, the speed of construction is in 
marked contrast to conventional live IBV vaccines where more than 100 egg 
passages of field strains are generally required for suitable attenuation.  In 
principle, a range of AMPV-IBV recombinant viruses could be readily made to 
determine all genes important in effective IBV protection. In contrast to the 
genetic instability characteristic of conventional live IBV vaccines, the use of 
AMPV recombinants allows the construction of vaccines of genetic stability 
carrying at least two IBV genes, and possible more. Furthermore the nature of 
AMPV replication implies that field recombinants, very often found during 
concurrent IBV infection and IBV vaccine use, would be highly unlikely to arise. 
The nature of the protective immune response to IBV is not well 
understood (35). In the present study fast tracheal recovery was equally 
induced by the N gene or N + S1 genes inserted into virus A vF.  However both 
induced markedly better protection than S1 in the same construct, while S1 
placed in virus A gave a similar level of protection to N in A vF. This might imply 
that N or N plus S1 if inserted into virus A might induce much better protection 
than seen in our study. Previous studies indicate that the internal N protein is 
able to stimulate a cellular immune response (199) whereas the exposed S1 
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protein would be more likely to stimulate antibody production  (36, 151, 152). 
However the S1 constructs inducing most AMPV and IBV antibody was based 
on 309/04 and A vF and these were the constructs which induced no 
detectable protection.  Further studies will be needed before firm conclusions 
can be drawn in this area. 
Because some of the subtype A viruses used to make recombinants are 
known to induce effective protection against AMPV in turkeys (163), it would 
be of interest to test the protection effects of subtype A recombinant viruses in 
that species. While IBV has no relevance to turkey disease, and AMPV 
recombinants carrying genes from coronavirus of turkeys could be substituted, 
agents causing disease associated with well-established challenge models such 
as Newcastle disease virus, would appear better choices. 
In conclusion, we report for the first time that AMPV is able to accept 
genes from, express proteins of, and confer protection against foreign viruses. 
Furthermore the recombinant AMPV-IBV viruses are genetically stable despite 
the incorporation of additionally approximately 3000 nucleotides; the upper 
limit is yet to be established. As the recombinants tested were able to induce 
IBV partial protection, it is likely that further studies will lead to the production 
of flexible vaccines of greater efficacy as well as a better understanding of the 
essential components for induction of effective protection against IBV and 
other avian viruses. 
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 CHAPTER 5  
ATTEMPT TO DEVELOP A REVERSE GENETIC SYSTEM 
FOR AVIAN METAPNEUMOVIRUS SUBTYPE B   
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5.1 ABSTRACT 
 
 
This work describes an attempt to develop a reverse genetic system for 
Avian metapneumovirus subtype B. The construction of a full length DNA copy 
(cDNA) of the viral RNA genome was attempted by firstly trying to exchange a 
previously developed subtype A genome cDNA by site directed-mutagenesis 
(SDM) in B subtype sequences. In a second stage, cut and ligation protocols 
relying on restriction endonuclease properties were employed. The 
development of DNA gene copies of the four essential support AMPV proteins 
(N, P, M2 and L) was also attempted using similar approaches. In order to 
stabilize and multiply SDM and ligation products, obtained constructs were 
cloned in commercial Stb12 E.coli after every reaction, with the intention of 
creating very stable bacterial plasmids. As a result of these processes, more 
than 85 % of B type genome was successfully cloned in the full length cDNA and 
three of the four support genes were obtained, namely N, P and M2. However, 
serious problems were faced with both the full genome and the L cDNA. 
Especially in the very late stages, cloning processes experienced unacceptable 
low success rate, suggesting a possible intolerance of viral sequences by the 
commercial bacteria. 
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5.2 INTRODUCTION 
 
 
Recovery of an RNA virus from a DNA copy (cDNA) of its genome allows 
the direct determination of the effect and the function of artificially made 
genomic mutations on viral biological mechanisms. In contrast to RNA, DNA 
molecules are stable and easy to modify using several techniques such as site-
directed mutagenesis or ligation protocols. In reverse genetics (RG), full viral 
genome cDNA can be copied to RNA using different strategies commonly 
relying on bacteriophage RNA polymerases (47). While for positive stranded 
viruses it has been easier to develop such systems since the RNA genome itself 
has the capacity to start an infectious cycle in cells, for negative stranded 
viruses the picture is more complex (229). Their genomes need to be 
associated with a ribonuclear protein complex (RNP) in order to initiate 
transcription and replication processes. RNP is usually formed by the 
nucleoprotein (N), which tightly encapsidates the viral genome, the polymerase 
(L) and the phosphoprotein (P), which acts as a polymerase-associated 
cofactor. Other proteins might be essential depending on the specific viral 
species (47, 48). Therefore RG systems for these viruses must not only provide 
the full cDNA genome as for positive stranded ones, but it is critical that all the 
proteins constituting the RNP are available. 
Avian metapneumovirus (AMPV) is a non-segmented negative stranded 
virus, belonging to the Paramyxoviridae family, causing respiratory infections 
affecting turkeys and chickens (49, 155). In 2004 Naylor et al. developed the 
first reverse genetic system for AMPV (158).  A full length (FL) cDNA of a 
subtype A viral genome was cloned in a plasmid by a series of PCR and ligation 
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steps. The plasmid included a kanamicyn-resistant gene, essential in the cloning 
process, a T7 promoter and Hepatitis delta virus ribozyme (158). Furthermore, 
N, P, L and Matrix 2 (M2) single genes, lead by a T7 promoter, were cloned in 
other plasmids in order to provide the genome with the essential protein to 
form the RNP complex.  Viral rescue was performed on Vero cells previously 
infected with a recombinant Fowlpox virus expressing the bacteriophage T7 
polymerase. This polymerase is able to recognize the T7 promoter inserted in 
the plasmids and then to initiate transcription directly from them. Therefore 
the addition of the full length cDNA and the four support protein genes, in the 
presence of lipofectamine 2000 to allow cDNAs entrance into cells, should lead 
to the formation of all the RNP components (158). After the complex has been 
established, genome replication and gene transcription can begin as occur 
naturally, producing new RNA virions. A similar RG system, based on the same 
technical principles, was developped for subtype C in 2006 in the United States 
(92). However, up to now it has not yet been possible to apply RG to subtype B. 
This subtype is one of the most widespread subtypes worldwide and, together 
with subtype A, is responsible for major production losses in poultry industries 
(50, 51). Two attempts to develop an RG system for this subtype, are believed 
to have been made, one by an Israeli research institute and another by an 
international veterinary vaccine company, but both are thought to have been 
terminated without final success (C.J. Naylor, personal communication).  
This present study describes an experiment designed to develop a RG 
system for subtype B. The first step was the generation of full length cDNA 
subtype B and of the four support cDNA genes to be inserted into plasmids. 
Cloning whole viral genome sequences appeared to be very challenging in 
previous experiences, as for the construction of the full length subtype A cDNA 
(C.J. Naylor, personal communication) but even for other viral species, due to 
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the instability of these constructs resulting in mutations or deletions. One 
possible explanation is that the cloning process might not tolerate certain viral 
sequences and that these can encode for bacterial toxic peptides, resulting in 
cloning failure (48, 129, 149, 153). To overcome problems, several strategies 
have been applied; these include the use of low copy-number plasmids and 
very tolerant E.coli strains cultured at low temperatures (188). Moreover in 
view of previously gained experience with subtype A cDNAs construction, it 
was decided firstly to try to exchange the existing subtype A genome cDNA in 
subtype B using site directed mutagenesis techniques (SDM). This was 
attempted in several stages, with each one adding a further genome section. 
Success at each step was confirmed with specific subtype B PCRs and specific 
enzyme cuts in the modified plasmid. Then, in a second stage, protocols 
involving ligations of amplified PCR product were used.  
 
 
5.3 MATERIALS AND METHODS 
 
 
Subtype B viral strains. The vaccine strains Aviffa (Merial), Nemovac 
(Merial) and Rhino CV (Intervet) were used as sources of viral PCR products to 
be used for SDM and ligation reactions. RNA was extracted from these strains 
using a commercial kit (Qiagen). 
Designed primers. Several oligonucleotide sequences were designed 
and synthesized by EUROFINS MWG OPERON company (Table 8). Primers that 
match both A and B subtypes were used to amplify amplicons for SDM 
reactions. For cut and ligations steps, primers adding at both ends restriction  
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Table 8: Oligonucleotide sequences of primers used for this study 
OLIGONUCLEOTIDE SEQUENCES USED IN THIS WORK 
Name Sequence (3'… 5') Function 
A 13.47 SAL + caactgaccttaaatgaatgttagtcgacaaaaactaaaagc Introducing RE site primer 
A 8.51 SAL neg cagcatccatggtcgacctttcttctac Introducing RE site primer 
B 0.03 + acaagtcacaatagaaaagaga Specific B type primer 
B 1.0 SAL neg gtgatctagagtcgacgcatgcaatc Introducing RE site primer 
B 1.43 + ctatgtagctcagaaacttctag Specific B type primer 
B 10,1 neg gtctgactcactgcctacttg Specific B type primer 
B 10,77 + caattatcaaagcgcatacgggaaacat Specific B type primer 
B 11,1 neg catgcagactagatctaaaagtctc Specific B type primer 
B 12 XHO + ccatgtctgagtaactcgagcattatcacctcgaagattagtcccagctgcc Introducing RE site primer 
B 12.39 + cagcataaaaagctgcctc Specific B type primer 
B 12.72 neg gattaataaaagtacattatcagggtc Specific B type primer 
B 13,49-rib neg gccgacccacggcaaaaaaaccgtattc Both A and B type matching primer 
B 13.49-rib+ gaatacggtttttttgccgtgggtcggc Both A and B type matching primer 
B 2.04 neg gtatctggttcagtctcttcac Specific B type primer 
B 2.2 + cgatctagttgagaaggacaac Specific B type primer 
B 2.28 + ctgctggaccagctaaaaactc Specific B type primer 
B 2.45 neg ctgctcttacatcgcaaactgtgagtac Specific B type primer 
B 2.52 neg ggtgttcatgtttgttacaatc Specific B type primer 
B 2.87 + ccagagaactaggtatgtcc Specific B type primer 
B 2.97 + caaactgctactaataatttatttggtgg Specific B type primer 
B 3.03 + cttacagtgaagaatcatgcagcac Specific B type primer 
B 3.23 neg cctatgggaaaggattcgattc Specific B type primer 
B 4.48 + gggcatagcttactatgtggttaaaaag Specific B type primer 
B 4.84  neg cccttctatataattctggacaacattggcag Both A and B type matching primer 
B 4.84 +  ctgccaatgttgtccagaattatatagaaggg Both A and B type matching primer 
B 4.94 neg atctaccatcaggtctcgtgc Specific B type primer 
B 4.99 + tgcataaccttgtcttgtcctatatagacatgag Specific B type primer 
B 5.48 neg tcatagtccgaagacacagcatg Specific B type primer 
B 5.63 + cctgagatcaacaagtcagcc Specific B type primer 
B 5.97 neg ctaatctacttgtatgtatatactcatatg Specific B type primer 
B 7,36+ gaaagaagaagaacagcacacaacag Specific B type primer 
B 7,90 neg attccaacagcttttacggagg Specific B type primer 
B 8,99 neg taacactacatacttcttcaagttctcc Specific B type primer 
B 8.35 SAL + gaacacatctgtcgaccatcatagatac Introducing RE site primer 
B 8.44 + gctgcagagatgtattttatctttagaatattcggac Both A and B type matching primer 
B 8.44 neg gtccgaatattctaaagataaaatacatctctgcagc Both A and B type matching primer 
B 8.53 + cagtgaggccactaaaatattgagcctc Specific B type primer 
B 8.83 + gtatatccaaaaaattatttacctccttctg Specific B type primer 
B 8.9 XHO + gcagaacatgaaaaaactcgaggtgtactagagttttacttg Introducing RE site primer 
B 9,47 + caaagggatttatgatattgactcaatccct Specific B type primer 
B 9,53 + ggaccatggaggcaatatctctccttgatg Both A and B type matching primer 
B 9,53 neg catcaaggagagatattgcctccatggtcc Both A and B type matching primer 
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B 9.21 neg cactcttcctagctttcac Specific B type primer 
B 9.59 + ggttaagaacagggttcagcaa Specific B type primer 
B 9.7 + cagactacagtttagcaataaaaatg Specific B type primer 
G 6.40 + cgcagttatgctgtactgggtggtgttga Both A and B type matching primer 
G 6.40 neg tcaacaccacccagtacagcataactgcg Both A and B type matching primer 
G 9+B tagtcctcaagcaagtcctc Specific B type primer 
L 11.31 + ggacattaacttggtcttccaaaatgctataag Both A and B type matching primer 
L 11.31 neg cttatagcattttggaagaccaagttaatgtcc Both A and B type matching primer 
L end B neg ctttatggtctattttgtgctcagtatgtacc L gene amplification 
L start B + gaccaatatggacccatccaatgag L gene amplification 
M 2.12 + gggacaagtaaacatggagtcct 
Both A and B type matching primer + P 
gene amplification 
M 2.12 neg aggactccatgtttacttgtccc Both A and B type matching primer 
M 2.83 + gagagcttagggaaaatatgcaaaacatgg Both A and B type matching primer 
M 2.83 neg ccatgttttgcatattttccctaagctctc Both A and B type matching primer 
M2 start B + gacaagtaaagatgtccagaaggaatccctg M2 gene amplification 
M2-1 end B 
neg 
ttgcacctaattactgctgtcaccc 
M2 gene amplification 
N 8 + gtgaaaatgtctcttgaaagtattaggctcagtg 
Both A and B type matching primer + N 
gene amplification 
NP 1.25 neg gacattttcacttgtcccgaatttttaattactc N gene amplification 
P start B + gtgaaaatgtctttccccgaaggcaag P gene amplification 
T7-21 + ctataggacgagaaaaaaagcattcaag Both A and B type matching primer 
T7-21 neg cttgtatgcgtttttttctcgtcctatag Both A and B type matching primer 
 
endonuclease (RE) sites were constructed. B type specific oligonucleotide 
sequences, which did not match with A type sequences, were designed to 
verify the presence of the modified sequences. Finally, amplification of the 
essential RNP component genes was carried out using B subtype-specific 
primers for N, P, M2 and L. 
RT-PCRs. RT- PCR protocols were assessed to amplify variable size B 
type amplicons. In order to improve PCR efficiency, annealing temperatures 
were adjusted to primer characteristics and elongation steps were optimized 
according to the expected amplicon size. Different polymerases were 
employed, e.g. GoTaq Flexi DNA (Promega), Bio-X-act (Bioline) and PFU turbo 
(Stratagene) due to the different properties of each enzyme: e.g. the last 
named enzyme was used preferentially as it performs high fidelity long 
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amplification and, contrary to other polymerases, it does not add overhanging 
ends to the final product. 
Subtype A FL cDNA and support protein plasmids. A subtype A full 
length DNA copy and the four related support genes (N, P, L and M2), 
belonging to strain 14/1 (158), expressed in low copy plasmids, were used as 
templates for SDM and ligation reactions. 
Site-directed mutagenesis. Subtype B amplicons, generated by both A 
and B type matching primers, were employed as megaprimers for SDM (188). 
These DNA sequences were able to join at both their extremities to the A type 
genome, resulting, after PFU polymerase reactions, in full length DNA copies 
including the B type sequence (Figure 23). SDM products were then run on 
agarose gel to confirm the success of the reaction (Figure 24). 
 
 
Figure 23: Schematic SDM and cloning process 
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Figure 24: Examples of positive SDM reactions (1,2,3,4 and 5) observed on agarose gel, proving the successful of 
the PCR cycle. M is marker 
 
Cut and Ligations protocols. Ligations protocols were employed when 
SDMs did not succed. Sal I, Xho I, EcoR V RE were mainly used for this purpose. 
Sticky ended ligations were more commonly used due to their high success 
rate: RE sites were introduced in the A type cDNAs by SDM reactions 
performed with enzyme sites adding primers. Sequences to be inserted were 
then constructed by designing specific primers including complementary cut 
sequences. After digestion of the artificially added sites, ligations were 
performed by T7 DNA ligases (Fermentas) (158, 188). This protocol is 
summarized in Figure 25. 
 
 
Figure 25: Schematic Ligation process 
1 5 2 4 M 3 
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Cloning in E.coli. SDMs and ligations products were cloned in E.coli 
stb12 cells (Invitrogen). In a few cases even competent cells, derived from a 
commercial line, were prepared in our laboratory using calcium chloride 
protocols and employed for transformation (188). During the cloning process, 
amplicons were adsorbed into bacteria, methylated and transformed in 
bacterial plasmids, resulting in stabilization and replication of the template 
(188). Bacterial growth was performed at room temperature. Furthermore 
prior to SDMs cloning, products were treated with DPN 1. This enzyme destroys 
methylated constructs and is used to eliminate any traces of the original 
plasmid used for preparation of PCR mix. Selection of the right construct was 
performed by specific B type PCRs (Figure 26) or specific junction PCRs. Correct 
plasmids were than extracted using commercial kits (Qiagen). As deletions can 
often occur during cloning, specific cuts using REs were finally made on the 
extracted product, using agarose gel staining to assure the presence of the 
whole plasmid. 
 
 
Figure 26: Example of colony screening after cloning in E.coli, with subtype B specific primers; only samples 1, 6 
and 12 are positive 
 
M M 1 4 2 3 6 5 9 8 7 10 11 12 
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Sequencing. Constructs were then sequenced as definitive proof of the 
changes made and to exclude the presence of undesirable mutations. Products 
were purified by Exonuclease 1 and Alkaline Phosphatase treatment and sent 
to commercial sequencing companies (Cogenics). Sequence Analysis was 
carried out using Chromas, Bioedit and Gene Runner softwares. 
 
 
5.4 RESULTS 
 
 
Construction of subtype B FL cDNA. The SDM technique was successful 
for the exchange of several DNA subtype A sections to subtype B, allowing, in 
several steps, more than half the genome (about 7.7 kb) to be replaced (Figure 
27). First of all, it was possible to replace a section of about 2 kb corresponding 
to N and P genes. Then almost all of the M gene and a short section of L and 
also the F gene and the beginning of the M2 were exchanged into the B type. 
Finally a further section of 2 kb was replaced in the L gene. However at this 
stage it proved impossible to add further subtype B genome sections.  SDM 
reactions gave no further products and transformation did not lead to clones 
with the intended sequence. In particular it appeared that certain genome 
sections including the second half of the polymerase gene were not being 
tolerated by the E.coli. Bacteria showed unstable growth rates. Even when SDM 
reactions were successful, colonies were growing very slowly and dying very 
easily or sometimes they were not growing at all 
As an alternative approach, it was decided to clone half genome 
sections, in the hope that they might be accepted more easily by the bacteria. 
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These were each derived from the last full length cDNA to be modified (Figure 
27.6) using RE cuts followed by ligation steps. In this way two different half 
genome (HG) cDNAs were constructed, a leader and a trailer one (Figure 27.7). 
Further SDMs were then performed on these constructs. As a result, the leader 
HG was completely exchanged, resulting in 8,4 kb of B type sequence 
successfully cloned. Unfortunately no improvements were possible for trailer 
HG where the L gene second half continued to cause problems. At this stage, 
cut and ligation steps were used in order to add the remaining B type genome 
to the leader HG cDNA, resulting in a construct including B type sequences 
from the leader to 12100 kb (Figure 27.9). No further improvements were 
possible, despite several attempts. This included the use of new developed 
competent cells which were employed at this stage, but without any 
improvement. 
Construction of single gene subtype B DNA copies. Cloning of M2 was 
achieved using SDM on the subtype A encoding M2 plasmid. N and P were 
instead constructed by ligation of the genes into plasmids, while no progresses 
were made for the complete subtype B L gene. Only partial L gene sequences 
have been cloned, specifically the first 4 kb, as several attempts to clone the 
full polymerase always resulted in trailer deleted constructs 
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Figure 27: diagram showing the B type sequences, in blue, introduced in the A type FL cDNA by SDM (1 to 6). Half genome plasmid were constructed (7), allowing cloning of about 85 
% of the B subtype genome (8 – 9). 
104 | P a g e  
 
5.5 DISCUSSION 
 
 
  As expected the development of a RG system for subtype B 
proved to be very challenging. Previous experiences setting up the A subtype 
RG system revealed the construction of FL cDNA to be critical (158). For this 
reason several strategies were employed to facilitate the cloning process, as 
using very tolerant competent cells both commercial and new developed ones 
(100, 197), low temperature growth for bacterial culture and low copy plasmids 
(188). Furthermore SDMs (230) were employed at first as it was thought to be 
more likely to succed than cut and ligation protocols. This technique allowed us 
to exchange more than 50% of the A type genome into the B type. However, 
after that, cloning attempts proved unsuccessful: in particular bacteria showed 
unstable growth rates. Even when SDM reactions were successful, colonies 
were growing very slowly and dying very easily or sometimes they were not 
growing at all. As mutations can occur during PCR based processes (102), 
changes in the kanamycin gene included in the plasmid were suspected. This 
might have explained the bacterial growth difficulties faced in the last stages.  
Sequence analysis were then performed on this region, but without showing 
any mutations. All these signs suggested that E.coli was unable to tolerate 
some of the viral sequences, since perhaps they might have encoded for toxic 
peptides, able to interfere with bacteria metabolic processes (188).  
Furthermore the more B type sequences were cloned and the more 
these problems were increased. In order to try to address this critical situation, 
half genome plasmids were than constructed. It was speculated that plasmids 
containing only a portion of the viral genome could be better tolerated by the 
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bacterium than the mixed A and B subtype full length construct. This 
suggestion appeared to be correct as it was possible, at least with the leader 
half genome plasmid, to replace B type sequences until 8400 kb by SDM and 
then elonging it until 12100 kb by ligation steps. This resulted in more than 85 
% of B type genome cloned.  Unfortunately after that the same bacterial 
stability problems were faced again. 
Three of the four required support gene plasmids were easily obtained, 
M2 by SDM and N and P by ligations. However it was not possible to clone the 
whole L gene (almost 6 kb). This highlighted once again how simple it is to 
clone small sections - N, P and M2 are no longer than 1300 kb each - compared 
to large sequences such as L or the full length cDNA. Furthermore attempts to 
clone the L gene resulted in cDNA deletion of the 5’ end gene portion. That 
leaded to the idea that the trailer part of the genome, corresponding to the last 
part of the L gene, could be particularly toxic for bacteria. In support of this, 
there is evidence gained by the unsuccessful results in trying to exchange or 
elongate the trailer half genome plasmid. 
In conclusion, this chapter describes the attempt to construct a full 
length cDNA for subtype B. More than 85% of the subtype B genome was 
cloned in a plasmid and three support plasmids, N, P and M2 were obtained. 
However bacteria instability problems, due to viral sequence intolerance, did 
not allowed us to obtain all the full cDNAs critical for the RG system. In the 
future further attempts will be made, trying to improve or change some of the 
materials and methods used for this work. For example more tolerant E.coli 
might be developed, and more stable plasmid vectors could be employed (188). 
Finally different cloning methods should be considered (196, 207), e.g. cloning 
in vaccinia virus, as reported for Infectious bronchitis virus RG systems, might 
be a valid alternative to bacteria cloning (29). 
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Since RG was first applied to AMPV (92, 158) different reports have 
investigated the effects of single and multiple genomic mutations (23, 160, 
163) and of gene deletions (133, 243) and insertions (92, 136) on viral biology. 
In this study we have tested AMPV as a vector for an extra homologus 
sequence (Chapter 2), for a reporter gene (Chapters 3 and 4) and for other 
viruses genes (Chapter 4). Finally an attempt to extend RG studies to AMPV 
subtype B was described in Chapter 5. 
In Chapter 2 an AMPV DNA copy was modified to accept a homologous 
M2 sequence inside the G gene. We proposed that rescued virus could function 
as a positive control for an AMPV diagnostic RT nested PCR.  RT-nested-PCR is a 
flexible virus detection technique of high sensitivity which requires the 
presence of the targeted RNA for positive detections. However, such sensitivity 
leads to potential risk of false test positives due to contamination with residual 
environmental nucleic acids. For this reason, the inclusion of a negative control 
appears to be critical (166). On the other hand a positive control is also 
required to avoid the occurrence of false negative results due to failure of the 
polymerase reaction (144). Standard controls derived from viral isolates have 
usually been employed, however these can enhance risk of false positives, as 
they can be themselves a source of contamination. The novel control virus 
described here removes the need to choose between conflicting demands. As 
for conventional AMPV control standards, the presence of correct bands 
confirms that all stages of the detection system, namely RNA extraction, 
reverse transcription and PCR, are functional. In addition, the increased size of 
amplicons immediately identifies instances where sample test positives result 
from contamination with the novel control. A potential problem with adopting 
such a live control virus in some regions might have been its genetically 
modified nature. However the microwave treatment effectively destroys virus 
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infectivity. Hence a control was developed which does not present any 
infection risks so can be used safely in all laboratory situations. The 
methodology is likely to be similarly useful for preparation of positive controls 
for the many RT-PCR tests used for detection of  other RNA viruses, both avian  
(38, 85, 204) and non-avian (10, 27, 72). The addition of a complete foreign 
gene to subtype A AMPV has already been demonstrated (137) hence it will be 
a routine matter to similarly add sequence from viruses such as those listed, 
irrespective of their role in host viruses. Again the foreign virus sequence would 
need modification to enable amplicon size differentiation but problems of its 
incorporation into AMPV anywhere within the regions coding for the 
nonessential SH or G genes (158) would not be expected to curtail virus 
replication. Furthermore, while the inserted small RNA sections would be 
highly unlikely to produce hazardous viruses, this risk would be entirely 
eliminated using the described microwave irradiation procedure. This would 
make the approach very suitable for generating controls for frequently used 
RT-PCR tests detecting hazardous viruses, including influenza and HIV.  
In order to assess the AMPV capacity to behave as a vector for foreign 
genes, seven strains of AMPVs were constructed each one carrying GFP in a 
different intergenic position (Chapter 3). AMPV tolerated GFP in all positions 
and good viral titres were generated in every case, except for one recombinant 
with insertion of GFP between N and P. This might be explained by an altered 
N/P ratio due to the addition of GFP between the two proteins as suggested by 
similar studies using VSV recombinants (232). N and P are in fact two essential 
components of the ribonuclear complex (RNP), which is critical for genome 
replication and transcription. Studies on VSV have shown the molar ratio 
between these two proteins to be critical for RNP functionality and an insertion 
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in that position seems to significantly alter this ratio, causing reduced virus 
production (106, 174) and this might explain the low titre. 
GFP expression was confirmed for all the viruses and this complies 
with previous AMPV studies (92, 136). However, when this was quantified, 
huge differences were found among recombinants. GFP proved to be more 
highly expressed when inserted firstly in the N-P position, secondly in SH-G 
and then in G-L, while insertions in M-F, F-M2 and M2-SH lead to very low 
synthesis of the protein. This surprisingly was in contrast with the accepted 
theory regarding transcription processes in NNS RNA viruses, where gene 
transcription and expression are regulated by gene position with respect to 
the polymerase single entry point at 3’ end. In this type of virus 3’ proximal 
genes appear to be the most transcribed while the distal 5’ ones are the 
least, with a sequential and gradual decrease at every gene junction of 20 – 
30 % in terms of transcription rate, due to polymerase dissociation (108, 
233). Therefore, we expected to detect the best GFP expression efficiency in 
r1 and least in r7, with the other recombinants varying GFP expression 
according to the distance of the inserted gene from the 3’ end. According to 
these findings, we speculated that a future AMPV vector should ideally have 
an extra gene introduced between N and P for an efficient protein 
expression. However the very low titre reached by this recombinant 
suggested severe viability issues, and for this reason an insertion between SH 
and G seemed the ideal solution for a future recombinant. This study was 
only a preliminary in vitro investigation, therefore experimental infections 
with animals should be critical in confirming and assessing the importance of 
the previous speculations in vivo. In a previous study, a recombinant GFP-
AMPV was used to infect birds and resulted in antibodies detection against 
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the vectored protein (92), showing the good potential of AMPV based 
recombinants.  
Chapter 4 describes the construction of several recombinants carrying 
foreign genes.  AMPV not only tolerates large extra sequences of up to 3000 
nucleotides, as in the case of the N + S1 recombinant, but is also able to 
replicate in vitro to high titres despite these insertions. This complies with 
similar evidences showed by other NNS single stranded RNA viruses (147, 192, 
229). GFP recombinants were constructed to test our expression system, 
consisting of the addition of an extra transcriptional unit in AMPV. IBV 
recombinants were then constructed in order to test AMPV, as a vector, for 
recombinant vaccines. Both IBV S1 and N genes were inserted, as they have 
both proved to induce protective immunity (35, 199, 242). In vivo some of the 
recombinants gave partial protection, assessed by observing tracheal cilial 
motility after virulent challenge with IBV. Unfortunately replication in the 
respiratory tract appeared to be poor for almost all recombinants -except for 
309/09, which however had the worst cilial performances-, and the serological 
responses against AMPV and IBV were largely absent. These finding suggests 
that even if AMPV readily accepts large and multiple genes in its genome, a 
deeper understanding of its biological properties is needed, before it can be 
seriously considered as a vector for recombinant vaccines. 
It would be interesting in the future to extend the same type of study to 
other AMPV subtypes (Chapter 5). The economic importance of the B subtype 
appears to be equal, if not in some cases higher than to subtype A. Despite a 
small number of attempts, up to now no RG system has been reported to allow 
genetic manipulation of this viral subgroup. For this reason the development of 
a subtype B RG was attempted here. The construction of a full length DNA copy 
(cDNA) was attempted using site-directed mutagenesis and ligation techniques 
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and this resulted in more than 85 % of B type genome being cloned. 
Furthermore, as for negative-stranded viruses the formation of the ribonuclear 
complex (RNP) is essential to start viral activities, RNP support proteins genes 
cDNAs were also constructed for N, P and M2. On the other hand, cloning of 
the L gene did not succeed.  Both full length cDNA and L cDNA faced severe 
development problems relating to construct instability and unsuccessful 
cloning due to probable bacteria intolerance. For example SDM and ligation 
reactions would not consistently work and when they were successful, 
transformation in E.coli resulted in delayed or absent bacterial growth or 
premature bacterial death. In order to construct the B subtype RG in the 
future, different approaches should be applied for this aim, such as: the use of 
more tolerant E.coli or more stable plasmid (188). Furthermore different 
cloning methods should be considered (196, 207), e.g. cloning in vaccinia virus, 
as reported for Infectious bronchitis virus RG systems, might be a valid 
alternative to bacteria cloning (29). 
In conclusion, AMPV subtype A has proved to be very tolerant in 
accepting extra sequences both within non-essential genes and within 
intergenic positions. Extra nucleotide sequences were conserved through 
several passages, viral viability appeared to be not affected in vitro despite 
insertions and expression of foreign genes was demonstrated in all 
experiments. In two cases, viruses have been tested as candidate vaccines in 
chickens against IBV showing promising results. Unfortunately it was not 
possible to extend these studies to subtype B. However the experience gained 
and the constructs obtained will hopefully be useful in the future to achieve 
these targets. 
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